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ABSTRACT
CHANGE IN BONE MINERAL DENSITY AMONG HIGH FREQUENCY
APHERESIS BLOOD DONORS

Walter Bialkowski, B.S., M.S.
Marquette University, 2018

Exposure to citrate anticoagulant during apheresis blood donation induces
significant decreases in serum ionized calcium with subsequent perturbations to
parathyroid hormone, vitamin D, and markers of bone remodeling. Cross-sectional
studies of bone mineral density (BMD) among apheresis donors exhibit conflicting
results. Resolving the potential impact of the highest apheresis donation frequency
represents a significant knowledge gap in ensuring adequate protections for volunteer
apheresis blood donors. ALTRUYST (NCT02655055) was a randomized, longitudinal,
controlled clinical trial designed to determine if repeated exposure to citrate through
apheresis donation reduces BMD. Male donors, 18-65 years of age with no more than
five previous apheresis donations and no diseases of bone or mineral metabolism, agreed
to make ≥20 apheresis donations in the subsequent one year period. Dual-energy x-ray
absorptiometry was performed at baseline and again after one year of participation.
Paired t-test was used to assess change in mean BMD. Donors in the apheresis arm
(n=26) made a median of 20 donations (range 4–22 donations) during the one-year study
period with a mean donation interval of 17.8 days. Controls (n=15) made zero apheresis
donations and a median of two whole-blood donations (range 0-6). Mean lumbar spine
BMD at the end of the study period did not differ significantly from that at the beginning
among donors in the control arm (mean change=-0.002 g/cm2, 95% CI [-0.020, 0.016],
p=0.78), nor did it change significantly among donors in the apheresis arm (mean
change=0.007 g/cm2, CI [-0.005, 0.018], p=0.24). Change in mean BMD at the total hip
was not statistically significant for control donors (mean change=0.002 g/cm2, CI [-0.006,
0.009], p=0.63) or apheresis donors (-0.004 g/cm2, CI [-0.10, 0.002], p=0.16). Tests for
differences in proportions of donors with change in BMD exceeding the least significant
change (LSC) at the lumbar spine (0.00743 ±0.02058g/cm2) between the apheresis and
control arms in either a positive [apheresis 13 (50%), control 5 (33%), p=0.84] or
negative direction [apheresis 8 (31%), control 6 (40%)] were statistically non-significant
(p=0.87). Proportional increases [apheresis 6 (23%), control 6 (40%), p=0.25] and
decreases [apheresis 11 (42%), control 3 (20%)] were not significantly different (p=0.15)
at the total hip (LSC=0.00671±0.01859g/cm2).
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CHAPTER ONE: INTRODUCTION

Apheresis blood collections produce life-saving therapies and represent an
increasing fraction of all blood derived components in clinical use today. Approximately
four apheresis derived platelet products were transfused in 2004 for every whole blood
derived platelet product (1) (Table I). Six years later, the use of apheresis derived platelet
products had increased to 10 apheresis derived platelet products transfused for every
whole blood derived product (2). These data illustrate an increase in the demand for
volunteer apheresis blood donors in the United States. This demand requires increasing
the number of donors undergoing apheresis, increasing the frequency of apheresis
procedures per individual donors, and/or increasing the number of units derived per
donation.

Hospitals
YEAR

Blood Centers

Total

RATIO
Apheresis :
WBD

Apheresis

WBD

Apheresis

WBD

Apheresis

WBD

2004

681

184

44

10

725

194

3.7 : 1

2006

1,196

248

36

9

1,232

257

4.8 : 1

2008

1,399

195

34

38

1,433

233

6.2 : 1

2010

1,953

197

17

2

1,970

199

9.9 : 1

Table I. Summary data from National Blood Collection and Utilization Survey Reports
showing the number of transfused apheresis-derived and whole blood-derived (WBD) platelet
products for participating hospitals and blood centers from 2004 to 2010. Values are reported
as thousands of doses (e.g. x 103).
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Table II shows the relationship between the number of apheresis platelet and red
blood cell procedures performed and the corresponding number of units derived over a
six year period in the United States (1-4). While the number of apheresis red blood cell
collections has increased, the proportion of products derived from each collection has
remained unchanged (53% in 2004; 49% in 2010). In contrast, both the number of
apheresis platelet procedures and the number of units yielded per procedure had
increased. An additional 200,000 platelet apheresis procedures were performed in 2010
as compared to 2004; an increase of 17%. There was also an increase in the number of
platelet product units derived from 1.3 per procedure in 2004 to 1.9 per procedure in
2010. Optimization in manufacturing practice might have played a modest role in this
observed increase in blood product yield per procedure; however, blood collecting
organizations were likely increasing the number of units derived from an individual
donation. Operationally, apheresis donor recruitment strategies often focus efforts on
retaining donors willing to donate often and who are capable of giving multi-product
donations in part because the number of donations in the previous year has a positive
association with donor return (5). These patterns of apheresis blood collection emphasize
the importance of understanding the long-term health impacts of apheresis on blood
donors.
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YEAR

Apheresis Red Blood Cells
Procedures
Units Yielded
Performed

2004

434

2006

†

Plateletpheresis
Procedures
Units Yielded
Performed

824

1,164

1,527

-

1,619

1,167

1,823

2008

1,022

1,926

1,352

2,130

2010

976

1,978

1,340

2,516

Table II. Summary data from National Blood Collection and Utilization Survey
Reports from 2004 to 2010 showing the estimated number of apheresis procedures
performed and number of corresponding component units yielded for participating
hospitals and blood centers. Values are reported as thousands of units (e.g. x 103).
†Estimate based on consultation with participating blood centers and average number
of units produced per apheresis procedure.

Apheresis red blood cell collection guidelines are based on FDA criteria for
allogeneic whole blood donation, which mandates a minimum of eight weeks between
single- and 16 weeks between double-red blood cell donations [21 CFR 640.3(b) and
640.12]. Subsequent eligibility for donation is based on total red blood cell loss at the
time of collection with a maximum loss of 1,540 mL per rolling 12 month period. Platelet
apheresis donation guidelines are currently founded on studies showing that frequent
apheresis platelet donors are able to maintain platelet counts within the normal reference
range (6-8). These platelet apheresis studies supported an AABB comment and FDA
policy increase in the number of apheresis donations an individual volunteer donor can
make from 12 to 24 per rolling 12 month period with no lifetime maximum (9, 10).
Federal regulations on paid source plasma donors allow 110 apheresis donations in a
rolling 12 month period [21CFR640.65(8)]. Despite a wealth of information on the
physiology of the apheresis donation experience, fundamental data are still needed to
inform policy that maximizes donor health and maintains the national blood supply.
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In contrast to whole blood collections, apheresis procedures require the use of
intravenous (I.V.) citrate anticoagulation. Cross-sectional studies have reported that
intermittent exposure to I.V. citrate is associated with significant declines in bone mineral
density (BMD) (11, 12) or no changes at all (13). In contrast to I.V. citrate, oral
potassium citrate formulations of much lower dose have been used to treat low BMD
with well-documented efficacy (14). The impact of I.V. citrate received during apheresis,
either positive or negative, is important given that BMD is a significant risk factor for
low trauma fracture, a problem that affects more than two million people in the U.S.
annually (15). The cross-sectional studies that have been performed on apheresis donors
have important limitations that call into question the validity of the reported relationship
between citrate exposure and BMD. Thus, it is ultimately unknown what effect repeated
exposure to I.V. citrate has on skeletal health. As demand to preferentially transfuse
apheresis blood products continues to increase, the importance of understanding the
effects of repeated exposure to citrate on the skeletal health of volunteer donors is
essential.
Hypotheses
Null Hypothesis: high frequency apheresis blood donation does not cause declines in
BMD after a one year follow-up period.
Alternate Hypothesis: high frequency apheresis blood donation causes declines in BMD
after a one year follow-up period.
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Objectives
The objective of this project was to assess the impact of I.V. citrate exposure
through apheresis blood donation on BMD using dual-energy x-ray absorptiometry. Our
central hypothesis was that frequent, repeated exposure to I.V. citrate causes declines in
BMD. Based on data from treatment of low BMD with oral citrate, we further
hypothesized that infrequent exposure to I.V. citrate may be associated with improved
BMD. The rationale for conducting this study was based on the need to obtain empirical
data that will help ensure the health of volunteer donors, or, to develop protocols that
protect members of this valuable community resource.
Specifically, we studied two groups: 1) donors who, for the first time, begin
undergoing a series of apheresis blood donation procedures during the follow-up period,
and, 2) healthy whole blood donor controls. This was a randomized, controlled study.
Blinding was achieved through the use of a blinded external reviewer of all outcome data.
The use of the same blood donor as their own control represented a simple and validated
approach to account for variation in BMD in the general population, thereby avoiding
fundamental design limitations of previous cross-sectional studies. We anticipated that
findings from this study would serve as the foundation for larger, randomized trials
addressing the role of repeated apheresis on BMD in blood donors, or, confirm that
current blood collections standards are safe for donors.
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CHAPTER TWO: BACKGROUND

Apheresis Blood Donation
In contrast to donating whole blood, making a blood donation by apheresis
permits the collection of individual blood components such as platelets, plasma, or red
blood cells. Despite longer average collection times, the blood collection community
benefits immensely by allowing an individual donor to come back more frequently than
every 56 days (in the case of platelets and plasma), decrease post-collection
manufacturing costs, and optimizing transfusion therapy by matching donor-recipient
attributes before a unit of blood is ever collected. Furthermore, transfusion of an
apheresis-derived blood product minimizes recipient exposures to foreign antigens,
thereby mitigating the risk of alloimmunization. During apheresis, whole blood exits the
body through traditional venipuncture and is processed in an extracorporeal circuit that
involves centrifugation, separation, and return of un-harvested blood components back to
the donor. Normal blood coagulation would commence in this environment but is
suppressed with anticoagulant (AC) treatment.
Apheresis blood collection guidelines are determined at the national level. This
has resulted in some disparities by country in terms of the maximum number of allowable
apheresis procedures per annum by an individual as well as the minimum inter-donation
interval by component type. Of note, there is no maximum number of lifetime donations
an individual donor can make as long as they continue meeting local donor eligibility
criteria. Thus, regardless of your country of donorship, you may achieve the same
number of lifetime donations as your expatriate counterpart.
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The current inter-donation intervals for common blood donation procedures in the
United States are provided in Table III. The maximum amount of time between apheresis
blood donations is a matter of personal preference, so long as that interval is no shorter
than that permitted by local regulations. It is possible that an individual volunteer blood
donor can make as many as 26 apheresis blood donations in a one-year period. This is
based on the assumption that the donor makes 24 single platelet apheresis donations and
two double red blood cell donations. The primary limiting factor in terms of the number
of allowable donations is based on blood donor plasma volume depletion. Platelets
require some volume of plasma for suspension before transfusion. Similarly, a double red
blood cell product does indeed contain a very small volume of plasma. Therefore, the
small amount of plasma removed from the body is multiplied by the relatively high
frequency of allowable apheresis procedures and leads to donor deferral for exceeding
donated plasma volumes.

Donation Type

Inter-Donation Interval
(days, based on average maximum by year)

Whole Blood

56

Double Red Blood Cells

112

Plasma

30

Platelets

14

Table III. Comparison of the average number of days between allowable blood donation
by donation type in the United States. Platelet donations may occur more frequently than
every 14 days, though the per year maximum number of allowable donations in the
United States is 24.
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The duration of an individual apheresis blood donation procedure is determined
by a number of factors. A typical double red blood cell procedure can take approximately
40 minutes, but this depends on factors such as the donor’s hematocrit (proportion of
formed elements in the blood), their blood volume, as well as their ability to tolerate the
procedure itself (16). Similarly for the collection of platelets, the amount of time that an
individual spends donating is a function of their circulating platelet count, the number of
component products they are donating (single, double, or triple platelet), and the ability to
tolerate the procedure (17). A donor’s ability to tolerate the procedure is heavily
influenced by the effects of the AC solution (18, 19).
As whole blood leaves the site of venipuncture, citrate AC is administered before
the extracorporeal blood enters the centrifuge housing. The amount of AC an individual
donor receives during a given apheresis blood donation procedure depends, first, on the
type of apheresis machine being used. There are continuous and intermittent flow devices
used in apheresis blood collection with intermittent flow devices having slightly less total
citrate burden to the donor (assuming all other determinants equal) (20). Because this
disparity in citrate burden is relatively inconsequential, it is also one of the least
important considerations when a blood collecting agency is determining which type of
apheresis machine to use for collections. The result is that both types of machines are
currently in use in the United States, as well as around the world.
In addition to the type of apheresis machine, the donor’s total blood volume is an
important determinant of the amount of AC administered during an apheresis procedure
(21). Donors with smaller blood volumes, such as women, are not able to dilute the same
amount of AC over as large a blood volume as their male counterpart. This corresponds
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to an increased concentration of active AC in the blood at any given time, making women
more likely to experience adverse side effects associated with citrate anticoagulation (22).
This example illustrates the importance of concentration of citrate on the overall burden
of citrate the donor experiences.
Another determinant in the concentration of citrate in the blood is the AC-towhole blood ratio (AC:WB). At higher proportions of AC per unit of whole blood,
apheresis blood collection times are decreased. The total blood collection time is also
affected by the inlet pump rate, which in combination with AC:WB, determines the
overall length of an apheresis procedure. Donors who can tolerate higher AC:WB ratios
do not require as high of an inlet pump rate as a donor who is more sensitive to
experiencing side effects associated with citrate anticoagulation. In contrast, sensitive
donors often require a larger volume of whole blood to be processed which alters the inlet
pump rate. The fact is that each apheresis blood collection is highly personalized and
subject to values imputed in embedded algorithms, donor tolerance of citrate AC, and the
overall goal of the apheresis procedure itself (i.e. the number of component products
derived).
Finally, the type of blood component being collected modulates AC exposure. It
has been shown that as much as 85% of the citrate introduced in the extracorporeal circuit
is actually diverted to the actual apheresis plasma product (23). Thus, donors making
apheresis plasma donations are experiencing a significantly reduced citrate burden as
compared to those who are making plateletpheresis or double red blood cell donations.
Apheresis plasma collections represent the most common form of apheresis in many
European countries, whereas apheresis plasma products are less frequently obtained in
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the United States and platelet collections by apheresis are common. Therefore, any longterm studies of the effect of AC on health outcomes in apheresis donors should carefully
consider the type of apheresis procedure occurring, as well as the frequency of those
collections.
Citrate Anticoagulation
Anticoagulant citrate has been used for decades to confer protection against
extracorporeal thrombosis during apheresis. Citrate’s mechanism of action involves
binding ionized calcium and subsequently interrupting thrombus formation in the
extracorporeal circuit. Many variables determine the amount of citrate an individual
apheresis donor is exposed to, including the type and duration of an individual apheresis
blood donation, as well as the number of lifetime donations made by an individual donor.
Unlike many alternative AC solutions such as heparin, anticoagulation with citrate is
superior in terms of pharmacokinetic half-life, risk of hemorrhage, and cost. Each
molecule of citrate has three carboxylic acid subgroups that are negatively charged. As a
result, the molecule itself confers anticoagulant properties by binding divalent metal
cations, such as calcium, that are essential cofactors in the intrinsic clotting cascade. With
the third carboxylic acid subgroup still ionized, complexed citrate remains solubilized in
human blood and does not confer the risk of precipitation (24). The half-life of citrate is
approximately 36 minutes (25). It undergoes rapid metabolism through the tricarboxylic
acid cycle in organs rich with mitochondria such as the liver and skeletal muscle. What is
not metabolized is simply excreted in complexed form in the distal convoluted tubule of
the kidney nephron.
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Exogenous citrate spends a variable amount of time in the extracorporeal circuit
during apheresis. Nevertheless, the longest interval between administration and entry into
the donor’s vasculature is less than ten minutes and most of the citrate is still in its active
form. This has been shown in several studies where the concentration of citrate was
monitored in apheresis blood donors. There is an initial surge of citrate in the donor,
many times greater than normal biological concentrations, in the minutes following
apheresis initiation (22, 26). The concentration of citrate continues to increase throughout
the procedure as more cycles of blood processing occur (22, 26). As expected, the
concentration of citrate in peripheral blood plateaus at the termination of apheresis and
begins declining rapidly thereafter. All residual citrate is metabolized or excreted within
the 24 hour period after the termination of AC exposure (22).
As predicted by citrate’s mechanism of action, the concentration of serum ionized
calcium in the donor’s blood decreases immediately upon the first return cycle of the
apheresis machine (26). This indicates that there is active citrate that has not yet
complexed with calcium in the extracorporeal circuit. This biologically active form of
citrate begins to sequester ionized calcium in the peripheral circulation. Throughout the
procedure donor peripheral blood continues to experience declines in serum ionized
calcium concentrations to levels that are slightly below the normal healthy range (27). It
is this decline in serum ionized calcium, as well as general blood cooling in the
extracorporeal circuit, that is responsible for the adverse reactions experienced by
apheresis blood donors (28).
Rates of citrate infusion can vary, though the industry standard range for ACD-A
and ACD-B are between 1.0 and 1.8 mL/kg/min (29). It is well documented that doses of
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citrate used in apheresis platelet collections positively correlate with serum citrate
concentration during apheresis procedures (22, 26, 30). Routine apheresis collection
procedures elicit a spike in serum citrate from 0.11mmol/L (±0.04) at baseline to
1.61mmol/L (±0.3). Because the concentration of citrate in peripheral blood is dosedependent (26), the derivation of multiple apheresis blood products corresponds to a
larger dose of IV citrate in the blood donor. Citrate’s half-life in the circulation is
approximately 36 minutes (25) and donors are able to fully metabolize exogenous citrate
from apheresis collections within 24 hours of exposure (26, 31).
Modern apheresis machines report the amount of anticoagulant used after
completion of an apheresis procedure. The common range of anticoagulant volume
administered during an apheresis procedure is 200 – 800mL. Apheresis platelet
collections can occur very frequently, up to 26 times per year, and are increasing in both
number and duration. Thus, it is important to consider the effects of IV citrate exposure,
both acutely and over time, in the blood donor population.

Citrate Physiology

Citrate’s role as a metal chelating agent that binds divalent cations, such as
calcium and magnesium, has been thoroughly characterized (32). Like endogenous
citrate, sodium citrate dihydrate and citric acid in acid-citrate-dextrose (ACD) solutions
chelate calcium ions in the blood by forming calcium-citrate complexes that disrupt
coagulation (33, 34). Studies documenting changes in circulating divalent cation
concentrations in apheresis blood donors have shown that there are similarities across
donation type. In a study by Szymanski, 79 volunteer donors undergoing typical
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apheresis procedures employing citrate anticoagulation demonstrated an average 22%
decrease in serum ionized calcium (iCa; from 4.19 mg/dL to 3.27mg/dL) when
comparing pre- and immediately post-procedure blood samples (30). Average decreases
of 33% and 39% in circulating iCa and ionized magnesium (iMg), respectively, were
observed in another study of volunteer blood donors undergoing plateletpheresis (26).
Hester and colleagues showed that donors with a blood volume of four liters undergoing
typical platelet apheresis procedures with citrate anticoagulation experienced decreases in
iCa of 15% at 10 minutes and 31% at 90 minutes (27). Similar findings were reported for
a study of healthy leukapheresis donors, where serum iCa and iMg decreased 35% and
56%, respectively (35). Ionized calcium is a tightly regulated molecule both intra- and
extracellularly. Donors generally tolerate decreases in concentrations of iCa up to 20%
before experiencing side effects (36) with women having a greater sensitivity to declining
concentrations than men (22).
Figure I provides a simplistic diagrammatic representation of the movement of
calcium throughout the body in a prototypical, healthy, adult individual over the course
of one day. Much of the 1,000mg of ingested calcium from food is excreted in the feces.
The 200mg net gain of calcium from the G.I. tract is lost in the urine. Calcium from
metabolically active trabecular bone is in homeostasis.
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+1,000mg

+500mg

INTESTINES
Net 200mg Gain

-800mg

+200mg

Extracellular
Fluid
-10,000mg

BONE
Net Null
-500mg

+9,800mg

KIDNEYS
Net 200mg Loss

Figure I. The movement of total body calcium throughout the course of
one day in a prototypical, healthy, adult individual whose calcium status is
in balance.

G-protein coupled receptors on the surface of the parathyroid glands and kidneys
directly sense declines in iCa concentration in the blood and stimulate secretory cells to
release parathyroid hormone (PTH) (37). Alterations to blood ionized calcium
concentrations are carefully monitored in the body due to calcium’s central role in many
biological functions. Monitoring occurs at the parathyroid glands; four pea-sized
structures immediately adjacent to the thyroid gland at the base of the neck. G-protein
coupled receptors, the calcium sensing receptors (or CaSR), located on the surface of
chief cells are bathed in peripheral blood. In the absence of sufficient ionized calcium,
these proteins change conformation and rapidly trigger the synthesis of PTH (37). The
secretion of PTH into circulation is extremely rapid and can occur within minutes of a
biological stimulus (38). Therefore, in the case of individuals with relatively low
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concentrations of ionized calcium in the bloodstream, we anticipate high circulating
concentrations of PTH as illustrated in Figure II.

PTH

+
Parathyroid
Glands
Normal
[Ca++]

Low
[Ca++]

Figure II. Schematic representation of the stimulus, decreased ionized
calcium in the bloodstream, affecting the secretion of PTH by the
parathyroid glands.

PTH has three primary effector organs in the body and all are associated with
replenishing the supply of ionized calcium in the bloodstream (Figure III). In the kidneys,
PTH directly stimulates the reabsorption of filtered calcium in the nephron. PTH also
stimulates 1-α hydroxylase that ultimately converts 25-hydroxy (OH) vitamin D to the
active metabolite 1, 25 di-hydroxy ((OH)2) vitamin D. Increasing 1, 25 (OH)2 vitamin D
levels upregulate calcium ATP-ase channels in the intestinal epithelium and promote
calcium absorption. Finally, PTH stimulates osteoblasts to secrete the ligand for receptoractivator of nuclear factor kappa B (RANK-L) that, along with macrophage colony
stimulating factor (MCS-F) lead to the terminal differentiation of hematopoetic
precursors to active osteoclasts. Active osteoclasts liquefy the bone matrix through a
process called resorption. Hydrochloric acid dissolves the mineral-rich hydroxyapatite
that is subsequently associated with the release calcium into the bloodstream.
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Figure III. The relationship between effector organs of secreted PTH and
their role in replenishing low ionized calcium in peripheral blood.

PTH directly stimulates the reabsorption of filtered calcium in the kidney
nephron. Renal control of reabsorption is under both osmotic and electrochemical
control. Calcium is a divalent cation that can be specifically regulated in the kidney
through the manipulation of the electrochemical gradient. Selective reabsorption of
calcium requires that positively charged molecules be excreted in order to maintain
balance. In the case of hypocalcemia, the nephron is stimulated by PTH to reabsorb the
positively charged cation. In exchange, the body excretes positively charged phosphate
ions into the filtrate leading to phosphaturia.
The influence of continuous exposure to citrate on the release of PTH was
assessed in 12 healthy donors undergoing platelet apheresis donation in a study by
Toffaletti, et al. They demonstrated that PTH reached maximum serum concentrations
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within 5-15 minutes of the start of citrate infusion (38). This has been corroborated in a
number of platelet apheresis donor studies (11, 26, 31, 39). Initial PTH surges in
apheresis donors are short-lived and PTH concentration returns to near-baseline as early
as 30 minutes after the infusion of citrate is terminated (26, 39). One study has shown
that PTH may remain elevated up to one day after the procedure despite a termination in
exposure (11).
The release of PTH into circulation simultaneously triggers all three of the body’s
main mechanisms to restore normal iCa: increased calcium reabsorption in the distal
tubules of kidney nephrons, increased intestinal calcium absorption through a Vitamin D
mediated pathway, and increased bone resorption (Figure III). Increases in serum PTH
increase calcium reabsorption in the distal convoluted tubule. Citrate exposure through
apheresis, however, increases urinary loss of calcium (40) despite concomitant increases
in PTH. Loss of calcium in the urine has been shown to be citrate dose-dependent (26)
and occurs during the 24 hour period after exposure to citrate (31, 35). Calcium
reabsorption in the kidney is 98% efficient under normal conditions, suggesting that
replenishment of iCa losses during apheresis will be minimal.
PTH also stimulates the activation of Vitamin D, which in turn increases intestinal
absorption of calcium. For platelet apheresis donors, concentrations of activated Vitamin
D have been shown to decrease 9% from baseline immediately after standard platelet
apheresis. One day following the exposure to citrate, activated Vitamin D exceeds
baseline concentrations by an average of 26% (31). Through a Vitamin D mediated
pathway, some calcium can be replenished in apheresis donors through small intestine
absorption (37). But despite providing large amounts of calcium as supplements, this
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study showed that donors were not able to recover 100% of baseline iCa concentrations
through this mechanism. Furthermore, calcium supplementation is, in practice, symptom
dependent and not routinely employed outside of the setting of this particular study.
Thus, the apheresis donor’s body may rely on metabolically active trabecular bone to
recoup lost calcium.
Bone Remodeling

Bone is a biological structure comprised of relatively few cell types and
associated proteins. However, terminal differentiation of these cell types coupled with
incessant metabolism make the human skeleton an incredibly dynamic human tissue. This
constant evolution of organic matrix and mineral underpin the essential role of the human
skeleton in human structure and function. Homeostasis of the human skeleton is
determined by the cell types whose changing roles determine the various types of bone.
Osteoblasts play the role of secreting organic proteins that form the structure upon which
mineral apatite deposits. Alterations to osteoblast function affect the skeleton by
decreasing its density and ability to resist fracture. Bone resorbing osteoclasts serve the
crucial role of helping to maintain systemic mineral homeostasis, but can cause
significant problems with skeletal integrity if disproportionately activated. Few studies
have explored the impact of apheresis on skeletal remodeling.
Bone is in a constant state of remodeling that is a coupled process linking the
resorption of bone by osteoclasts and the deposition of new bone by osteoblasts. The
deposition of bone is performed by osteoblasts: mesenchymal stem cell-derived cells
under the master regulation of RUNX-2 (41). Bone deposition involves the secretion of
the organic matrix elements of bone, namely Type 1 collagen, by osteoblasts on the
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surface of bone. Collagen assembles into helical fibrils that form cross-links leading to an
overlapping structure. The alignment of collagen fibrils is offset, leaving a small
proportion of the fibril exposed and creating a potential nucleation site for mineral
deposition (42). Mineral deposition is spontaneous and involves substituting subgroups of
the hydroxyapatite molecule with various minerals which lead to the creation of apatite.
Osteoblasts either undergo apoptosis, or, are embedded within the newly formed matrix
and undergo terminal differentiation to osteocytes.
The interplay between bone resorption and deposition is so tight that indeed, the
very cells that deposit bone are essential to the stimulation of the cells that resorb it.
Upon stimulation by various cytokines, osteoblasts secrete the ligand for receptor
activator of nuclear factor kappa B (RANK-L). RANK-L, along with macrophage colony
stimulating factor (MCS-F), bind receptors on hematopoetic osteoclast precursors
stimulating fusion, multinucleation, and differentiation into osteoclasts. These very large
cells form a tight bond on the surface of bone called the sealing zone. Hydrochloric acid
is subsequently secreted to dissolve the mineral element of bone, apatite (43). Apatite is
rich in important minerals such as calcium and magnesium. Cathepsin K is also secreted
(44), leading to the breakdown of type 1 collagen, the primary organic component of
bone. Osteoclast plasma membranes express a unique morphology during this process by
forming highly convoluted festoons called the ruffled border that increase the surface
area of the cell maximizing the absorption of the newly liquefied components of bone
(45). Migration of these components through the cell and into peripheral circulation
illustrates the incredibly important role that bone serves in maintaining systemic mineral
homeostasis.
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In addition to secreting osteoclast stimulating factors, osteoblasts secrete a decoy
receptor protein called osteoprotegerin. This decoy receptor can sequester otherwise
potent activators of osteoclast differentiation (46). In effect, osteoblasts have complete
control over osteoclast activation by manipulating the relative concentrations of these
substances in the immediate proximity of active bone metabolism. This known
phenomenon may represent an optimal therapeutic target for diseases of osteoclast over
expression, however, RANK-L is non-specific and such therapies could have significant
off-target effects.
There are several markers of bone resorption, however only a few have been
measured in apheresis donors. C-terminal telopeptides, such as β-CTX, are both sensitive
and specific measures that quantify the breakdown of type 1 collagen (47). In a
randomized, placebo-controlled study of blood donors, citrate infusion increased serum
concentrations of β-CTX in apheresis donors whereas controls not receiving citrate had
no change in their serum β-CTX (p < 0.0001 for between-exposure comparisons) (48).
This finding held true for donors in another study where both serum and urine
concentrations of β-CTX were elevated by as much as 26% and 17%, respectively, and
remained elevated for up to 24 hours post-donation (11). The greatest measured increases
in β-CTX have been observed at the completion of an apheresis procedure (48)
suggesting that bone resorption begins during exposure to citrate. When concentrations of
β-CTX are compared to concentrations of osteocalcin (OC), a protein secreted by boneforming osteoblasts, the proportion of these two markers throughout the procedure
increases suggesting that bone metabolism may shift toward resorption during apheresis.
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Additional data in the weeks following apheresis are needed because formation occurs at
the end of the remodeling cycle.
Phosphate is also an essential component of hydroxyapatite in bone. As elevations
in PTH stimulate the dissolution of hydroxyapatite by osteoclasts, release of phosphate
from bone increases. PTH simultaneously reduces reabsorption of phosphate ions in the
proximal convoluted tubule of kidney nephrons, allowing excess phosphate to be
excreted and ensuring that concentrations of serum phosphate do not exceed normal
physiologic concentrations. Serum phosphate concentrations decrease modestly during
apheresis and return to pre-apheresis concentrations within the 24 hour period following
apheresis (11). However, the concentration of fibroblast growth factor (FGF) 23, the
protein that stimulates the expression of sodium-phosphate co-transporters in the
nephron, has not been measured in apheresis blood donors.
There is some evidence that exposure to citrate from apheresis actually favors
bone deposition, not resorption. OC has been shown to remain slightly elevated at 24
hours post-apheresis donation (31). Furthermore, concentrations of osteoprotegerin
(OPG), an inhibitor of the maturation of bone degrading osteoclasts, were observed to
decrease following 120 minutes of citrate exposure and recover to baseline at 24 hours
post-exposure (11). Tartrate-resistant acid phosphatase (TRAP), an enzyme expressed by
osteoclasts, has been shown to be a useful marker of bone resorption because of its
limited variability in vivo (49, 50). In apheresis platelet donors TRAP was observed to be
lower than baseline at both 120 minutes and 24 hours post-exposure suggesting that
apheresis acutely suppresses bone resorption. The authors do not address the paradoxical
nature of this finding, especially considering their claim that a finding of lower bone
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density in apheresis donors relative to controls is a “true finding”. It should be mentioned
that a limitation of using TRAP to assess bone resorption in healthy people may be the
inability to make meaningful interpretations when threshold concentrations below that of
pathological conditions are not met (51).
The process of remodeling bone is a process that occurs over a 4-6 month period.
The availability of physiological data in apheresis blood donors spanning an interdonation interval of two weeks is relatively sparse. Rather than creating a complete
profile of prolonged effects of IV citrate exposure in apheresis donors, researchers have
begun looking into bone-related health outcomes. Consequently, the opportunity exists to
fully catalog apheresis blood donor physiology in the weeks following IV citrate
exposure. With some studies showing evidence of bone remodeling 14 days after
exposure to citrate (52), it is difficult to use the available data to predict long term effects
on bone health in this donor population. More careful characterization of the effects of
exposure duration, and especially frequency, is needed as the body’s recovery following
exposure has not been sufficiently studied.
Steddon and Cunningham (53) noted in their review of calcium receptor
manipulation therapies that short periods of elevated PTH favor bone formation by means
of expediting the maturation of osteoblasts. Further, it has been conceptualized that large
and rapid increases in PTH followed by normalization, such as that stimulated by
calcilytic drug therapies, may translate in bone-anabolic effects (54). Finally, we should
not ignore that oral potassium citrate is a common treatment for low bone density with
documented efficacy (14). Thus, intermittent exposure to citrate through apheresis blood
donation could theoretically have beneficial effects on bone. The conclusions of many of
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these studies have been derived from clinical trials of postmenopausal women only, all of
whom have declining estrogen. Because of estrogen’s central role in bone metabolism,
the generalization of these findings to apheresis blood donors warrants very careful
attention and additional research.
Citrate anticoagulation affects calcium homeostasis which underlies the concern
about potential declines in bone density. Possible long-term health effects of IV citrate
exposure during apheresis may have important implications given that decreased bone
density is a significant risk factor for low-trauma fractures. If repeated citrate infusion
during apheresis procedures adversely affects bone density, it is likely that the frequency
and/or amount of citrate exposure correlate with the severity of bone catabolic effects.
Results from a bone density study of 102 apheresis platelet donors with a lifetime average
of 85 apheresis procedures (range 16 – 633) as compared to non-blood donor controls
demonstrated significantly lower bone density at the lumbar spine (Z-score P=0.038) for
apheresis donors as compared to controls (11). No significant differences in bone density
were seen at the hip and femoral neck (Z-score P=0.36 and P=0.72, respectively). The
authors conclude that donor-specific differences in bone metabolism are unlikely, but that
these donors differ in the way they regulate mineral homeostasis when challenged
metabolically by exposure to citrate. It is not clear if the authors intend this to be a donorspecific predisposition or some type of response-mediated adaptation to citrate exposure.
Given that the available data suggest that disturbances to the body’s homeostatic
maintenance of bone may span the inter-donation interval of frequent apheresis donors,
effects on bone density in high intensity apheresis donors could be sizable. However, the
most important limitation of this study was in the cross-sectional evaluation of BMD

24

which the authors acknowledge. Because individuals achieve different peak bone
densities, longitudinal comparisons using donors as their own controls are essential to
drawing accurate conclusions about citrate exposure through apheresis and BMD.
Two complimentary studies have examined the effect of repeated apheresis blood
donation and bone-related health outcomes. The first is a prospective National Institutes
of Health study that incorporates a longitudinal assessment of bone density
(NCT00073060). No data are as yet available. The other study was conducted on the
Scandinavian Donations and Transfusions (SCANDAT) database (55). This retrospective
cohort study (56) provided the first large-scale data on the effects of frequent and longterm apheresis donation on the risk of fractures. In this study, all available data on
Swedish blood donors who experienced one or more apheresis blood donations during the
period 1990 through 2012 were analyzed until death, emigration, or the end of the followup period. Donor fractures were sourced from the Swedish patient register and classified
according to the International Classification of Diseases, Revisions 9 and 10. Fractures,
including all and osteoporosis-related fractures, were analyzed and correlated with
apheresis blood donation using Poisson regression. There was no association between the
number of lifetime apheresis donations, the recentness of apheresis donation, nor gender
or age on a blood donor’s risk of fracture in any analyses. The Swedish blood donor
population is different from the U.S. blood donor population in terms of race, ethnicity,
body mass index, and other determinants of bone density. Furthermore, the vast majority
of apheresis donations made during the analysis period were plasma donations where
citrate burden to the donor is as much as 85% reduced compared to platelet apheresis
donations (23). These large-scale epidemiology studies have previously shown utility in

25

examining potential associations between the blood donation activity and long term
health outcomes (57-60), however, these studies are observational in nature only. Thus, a
longitudinal, randomized study is needed in blood donors to assess whether or not
repeated apheresis is associated with declines in bone mineral density.
Conclusions

The collection of blood products using apheresis technologies has been increasing over
the previous decade. Citrate anticoagulation confers protection to the donor by
sequestering ionized calcium in the donor’s blood stream. Parathyroid glands sense the
decline in ionized calcium in donor serum and secrete parathyroid hormone. The
physiologic response to parathyroid hormone has been measured in blood donors
undergoing apheresis and there are indications that bone homeostasis is perturbed. There
are very limited longitudinal data on whether or not apheresis-induced modifications to
normal calcium homeostasis impact bone density.
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CHAPTER THREE: ALTRUYST Methodology

In this prospective, longitudinal, randomized, controlled clinical trial
(NCT02655055) we tested the hypothesis that high frequency apheresis donation is
associated with declines in BMD after a one year follow-up period. Eligible donors who
had made no more than five apheresis blood donations in the past were enrolled using
informed consent (Appendix 1). All donors also agreed to make close to the maximum
number of allowable volunteer apheresis blood donations during the follow-up period
(n=26) to help limit attrition and control for potential selection biases. Dual-energy x-ray
absorptiometry (DXA) was performed at baseline for all enrolled men aged 18 to 65
years who had no known skeletal medical conditions. Following DXA, donors were
randomly assigned to continue with their apheresis donation program (‘treatment’), or,
control (no apheresis blood donation during the follow-up period). Individual subjects
also served as their own controls through repeated measures analysis (baseline and
approximately twelve months later). The primary outcome measure was the change in
total lumbar spine bone mineral density as assessed by DXA. A secondary outcome
measure included change in total hip bone mineral density. Two additional outcome
measures included femoral neck BMD and the trabecular bone score, a gray-level textural
metric that can be extracted from the two-dimensional lumbar spine DXA image (61).

Study Population

This was a prospective, randomized, single-center study that assessed the effect of
high frequency intravenous citrate exposure on bone density in volunteer apheresis blood
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donors. Eligible participants were male, 18-65 years of age, with no more than five
lifetime apheresis blood donations. There are known side effects of apheresis including
paresthesia (due to hypocalcemia) and chills that deter future donation. Thus, this study
recruited male donors who had made at least one previous donation to help mitigate
attrition. All eligible participants were recruited from a population of donors beginning
an apheresis blood donation program. Donors were encouraged to donate nearly the
annual maximum of 24 donations per year (i.e. 20 – 26 donations during the study).
Apheresis donation procedures included platelets, red blood cells, plasma, and multiproduct donation types. All donation types were allowable in the present study because
citrate anticoagulation is universally administered, procedure times are comparable, and
even modest amounts of citrate exposure are associated with supraphysiologic spikes in
parathyroid hormone.

Inclusion and Exclusion Criteria

Inclusion criteria
•

Male

•

eligible volunteer blood donor

•

≥ 18, and, ≤ 65 years of age at enrollment

•

≥ 1, and, ≤ 5 prior apheresis blood donation procedures

Exclusion criteria
•

Female

•

Age < 18 or > 65 years at enrollment

•

ineligible for whole blood donation
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•

BMD Z-score <(-2.0) or >(2.0) at any measurement site upon baseline assessment

•

metal prosthesis at measurement site

•

weight > 300 lbs (136 kg)

•

previous fracture of the lumbar spine or hip (femoral neck, intertrochanteric hip)

•

any fragility fracture, defined as a fracture resulting from a fall of standing height
or less, during adulthood (specifically ≥18 years of age at the time of fracture)

•

previous lumbar spinal fusion surgery

•

cystic fibrosis

•

emphysema

•

celiac disease

•

Crohn’s disease

•

Current or past (>1month duration) use of medications known to affect BMD
including, not limited to:

•

(phenytoin, phenobarbital, corticosteroids)

•

Current Osteoporosis Medication use including, but not limited to:

•

(Forteo, oral biphosphonates, Reclast, Prolia, calcitonin)

•

Unable or unwilling to donate high frequency apheresis

Control Population

The primary outcome measure was change in BMD and therefore, each
participant served as their own control. Additionally, this was a randomized study.
Eligible participants were randomly allocated to exposure (high frequency apheresis) or
control (no apheresis allowed; whole blood donation allowed). Randomization occurred
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after informed consent and baseline assessment but before the first ‘on-study’ blood
donation. The control group was included in this single-center study design to ensure that
any regional changes in BMD among the larger population could be detected and
accounted for in the analysis.

Recruitment and Enrollment Methods

This study used a four-tiered recruitment program that aims to capture donors at points of
intake.

Tier 1: In-Person Strategies:

Recruitment strategies used in prior studies involving face-to-face encounters
have proven to be one of the most highly productive methodologies employed, especially
for targeted donor groups (e.g. PR00022441, PRO00023331, PRO00022435). We
therefore employed similar strategies in this protocol using face-to-face recruitment
methods and an informational flyer (Appendix 2). Subjects were recruited in person by
research staff at fixed or mobile collection sites. Research coordinators primarily
approached donors at the time of registration following routine procedures for research
with volunteer blood donors. Donors expressing a lack of interest in participation were
thanked. Donors expressing interest in participating participated in further discussions
about the study with a trained research coordinator using the informed consent to guide
talking points. The researchers collaborated with local site managers to ensure that
recruitment activities did not interfere with BloodCenter of Wisconsin operations and
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donor intake. In collaboration with BCW Donor Group Recruiting, in-person recruitment
also occurred at mobile blood drives. The overall success of this study was based on the
team's ability to recruit new apheresis donors who were beginning to undergo these
procedures. To improve efficiency and accuracy of recruitment efforts, as well as
avoiding recall bias on the part of the donor, the research team requested an appointment
list from IT/IS for eligible donors scheduled to donate at sites where in-person
recruitment is planned. The appointment list included donor name, date of appointment,
location of appointment, time of appointment, donor gender, number and type of
donations in the previous 24 months, and donor ID. This list was distributed only to those
research staff that are trained and certified in managing human subjects research related
identifiers. Donors on the list were approached using the same strategy as for any other
donor approached in person. These lists were maintained on the BloodCenter of
Wisconsin secure server and any printed copies were kept in a locked file cabinet at the
Blood Research Institute.
To enhance the functionality of the informational flyer, the research coordinator
collaborated with leadership in Donor Services and Volunteer Services Departments to
identify ‘study champions’ at each fixed blood center location. Through didactic and
interactive workshops led by the study team, endemic blood center staff and volunteers
learned which donors were potentially eligible for the study and offered to put donors in
touch with members of the research team. Study champions served the dual purpose of
enhancing recruitment and maximizing data integrity by serving as a trained liaison.
Donor Services personnel placed an ALTRUYST sticker on the donor’s summary sheet
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to help Volunteers identify which individuals in café were potentially eligible for the
study. The word “ALTRUYST” was all that appeared on this sticker.
Ultimately, the research coordinator performed study screening before enrollment to
ensure the highest degree of protocol compliance.

Tier 2: Targeted, Active Strategies

BloodCenter of Wisconsin fixed donation centers track apheresis donations made
by individuals using a hanging file folder identified by the donor’s name. Within the
folder is a record of the number of apheresis donations and procedure run sheets. A
donor’s initial apheresis donations are captured in a similar way but are arranged
alphabetically in a shared hanging file folder. Both of these resources provided an
opportunity to tailor recruitment strategies to eligible male donors. The Tier 2 recruitment
strategy allowed the research team to review these records for eligible subjects on site.
Each time an eligible donor was identified the research team member placed a study card
(business card designed specifically for the study) on the donor’s record. This practice
cued front line staff members to provide the donor with the informational flyer
(Appendix 2) upon presentation. Donor staff then put the donor in contact with the
research team or the donor could have chosen to self-identify at a later time. This
approach ensured anonymity and consistent recruitment messaging.

Tier 3: Targeted, Passive Strategies
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This strategy was implemented using an ongoing apheresis conversion initiative
led by BloodCenter of Wisconsin to expand the apheresis blood donor base. Beginning in
the spring of 2015, all whole blood donors were being evaluated for their capacity to
donate apheresis platelets. Automated reports were be generated from endemic
BloodCenter of Wisconsin data systems to identify donors who initiated apheresis
donation in response to this operational recruitment strategy. Targeted strategies for
recruitment included mailings and emails at both fixed and mobile blood drives. The text
for mailings and emails were provided as attachments to the protocol (Appendix 3).
Additionally, BCW Call Center scripts were developed and integrated with endemic
direct and automated appointment tools. Messaging content was derived from text
provided in Appendices 2 and 3 because of the dynamic nature of donor recruitment
strategies.
These population-based approaches to sampling are subject to non-participation
bias (i.e. eligible donors who choose not to enroll). Due to the relatively low proportion
of donors who would have converted to an apheresis donation regimen and the relatively
short enrollment period, all interested and eligible donors were enrolled in the study (i.e.
no random sampling).

Tier 4: Non-targeted, Passive Strategies

The research team provided ALTRUYST informational flyers (Appendix 2) to
BCW Donor Services Managers who posted them in blood center common areas.
Interested subjects could then self-identify their interest in participating by either calling
the research hotline or emailing clinicalresearch@bcw.edu. Front line blood collections
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staff received training from Donor Services Managers (who will receive training from the
research team) to answer any questions about the study from donors by providing contact
information for the research team to ensure that consistent messaging occurs. Study
champions augmented the supervisor’s need to provide information by serving as a
trained liaison.
Finally, the BCW website (www.bcw.edu) has modalities that directly support
clinical trial recruitment. Using text blended from across other IRB-approved media
(informational flyer, email script, letter) the research team collaborated with corporate
web developers to create electronic capture mechanisms (hyperlinks) that were displayed
broadly across research oriented web content (BCW domain only). These links were
intended to funnel self-identifying individuals to direct contact with the research team
(email or telephone).

Measurement Methodology

Self-Report Survey

Subjects who provided written authorization for participation first completed a
survey to confirm eligibility and to evaluate increased risk of fracture including questions
on race, ethnicity, family history of osteopenia/osteoporosis, family history of fracture,
personal history of fracture, daily calcium intake, activity level, medication use, and other
parameters that affect baseline BMD prior to DXA [Appendix 4]. These are considered
standard of care intake questions for patients being evaluated for osteopenia/osteoporosis
contributing to the validation of risk factors, with and without bone density
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measurements, to improve accuracy of fracture prognostication tools. The survey was
administered twice: once prior to the baseline assessment and once prior to the final
assessment. The paper-based survey was self-administered by the study subjects and was
reviewed by research staff to ensure complete capture of the required information. The
survey was designed to capture responses affecting a donor’s eligibility in the study and
therefore, donors who were ineligible based on responses did not have baseline DXA
performed.

Bone Mineral Density

After informed consent and before the first on-study blood donation, participants
had dual energy x-ray absorptiometry (DXA) performed [see Appendix 5]. DXA assesses
BMD by way of emitting two fan beam x-ray energies that quantify bone density in
mg/cm2. Baseline BMD measurements were collected before the first on-study donation
using DXA at the lumbar spine (L1 – L4), left and right hip (femoral neck, greater
trochanter, and intertrochanteric region), and full body using standardized equipment.
Subjects with metal prostheses and/or prior fracture at any measurement site were not
eligible for participation because of interference with BMD measurement. Likewise,
subjects weighing more than 300 pounds were not eligible due to DXA scan table mass
limits. Subjects with a fragility fracture, defined as any fracture from a fall of standing
height or less, during adulthood (i.e. ≥18 years of age at time of fracture) were also
excluded.
DXA systems, as with all measurements, introduce a form of variation implicitly.
This study used the GE iDXA™ with Encore version 11.40.004 software for all DXA
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measurements. This machine was maintained according to manufacturer specifications
which included periodic phantom scans, visual inspection of phantom scans, phantom
scans after any service, and service logs. A recent study reported the greatest numerical
difference in BMD at the total hip for same-subject assessments at 0.007g/cm2 (62).
Calibration data were collected for the measurement instrument and normalized prior to
data analysis. This instrument is located in the Department of Physical Therapy, Cramer
Hall, Marquette University, Milwaukee, WI.
Individual bone density results can be standardized to population values for
subjects of the same age, sex, and race and will be reported as Z-scores. Due to ethical
considerations, any subject with a BMD Z-score <(-2.0) or >(2.0) at any measurement
site during the study was notified of the finding [Appendix 6] and advised to seek
medical attention. It is likely that these subjects, upon medical consultation, would begin
an efficacious treatment regimen that would have an impact on follow-up BMD values.
While excluding BMD outliers limits the generalizability of this study’s findings, the
strategy employed has the advantage of addressing the question of how the vast majority
(~95%) of eligible donors respond while eliminating possible confounding introduced by
therapy prompted by abnormal BMD findings. Ongoing monitoring of the true
prevalence of this finding in this study’s sample during the enrollment period was
performed. Because the prevalence of baseline BMD out of this range was higher than
expected, the final enrollment sample size was adjusted to achieve the desired analytic
sample size.
All BMD test results outside of this range, or within 0.1 standard deviations, were
reported to this study’s Medical Monitor, Dr. Robert D. Blank, who is a clinical expert in
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metabolic bone disease (see Section PROTECTION AGAINST STUDY RISKS). To
preserve blinding, all BMD measurements (baseline and follow-up) were sent to an
external adjudicator, Dr. Joseph Shaker, a clinical expert in metabolic bone disease, at the
end of the study but before analysis. All BMD reports were blinded in terms of subject
randomization and date of scan. The adjudicator thus served the role of interrogating all
BMD scans to ensure quality and validity of study values. Finally, cross-calibration of
multiple DXA systems was not required in this study because only one instrument was
used and all scans were performed by a single technologist.

Biospecimens

Enrolled participants had peripheral tubes of blood collected both pre- and postapheresis. Collection of these samples did not require an additional venipuncture because
it was diverted from normal blood collection kits. All specimen processing was
conducted in designated laboratories at BCW by trained personnel. Laboratory testing
was performed at ARUP clinical research laboratories in Salt Lake City, UT. Results
from testing were used only for the purpose of post hoc analysis and hypothesis
generation. Analytes included elements of a comprehensive metabolic panel, testosterone,
parathyroid hormones, complete blood counts including reticulocytes, and markers of
bone and mineral metabolism. Laboratory testing occurred in batches well after specimen
acquisition, and therefore results were not shared with participants at any time. Frozen
aliquots were stored at BCW for up to three years after the study is closed to allow time
for testing.
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Citrate Anticoagulation

BloodCenter of Wisconsin utilizes anticoagulant citrate dextrose solution (ACDA) for the collection of apheresis products. Sodium citrate dihydrate is derived from
anhydrous citric acid (C6H8O7) and together these constitute 2.2g and 0.73g per 100mL
of the ACD-A formulation used during apheresis, respectively. Data on ACD-A exposure
is captured on apheresis run sheets the blood center. Table IV shows the citrate exposure
endpoints (time of exposure, dose) that were collected for this study.
The type of apheresis donation being made (platelet, red cell, plasma, or multiproduct), volume of ACD-A (mL) infused, and duration of apheresis procedure (minutes)
was abstracted from blood center flow sheets for each visit over the study period. Platelet
product yield was classified as single (3.1 – 6.6 x 1011), double (6.7 – 9.9 x 1011), and
triple (≥ 10.0 x 1011).
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CITRATE EXPOSURE ENDPOINTS
Collections Information

Machine
Run Sheet

Trima, Amicus
Yes

Concurrent Products

Exposure Time

1

Start Time

Yes

End Time

Yes

Total Time
Type of AC

Yes
2

3

Citrate (AC) Parameters

Yes

ACD-A

[AC]

Yes

Lot #

Yes

Expiry

Yes

Volume AC Used

Yes

Volume AC in PLT

Yes

Actual Volume
Infused4
Yes = collected regularly on blood center apheresis flow sheets
1
Concurrent plasma collection is allowed.
2
AC = anticoagulant
3
concentration of AC
4
= VAC used – VPLT AC

Yes

Table IV. Availability of citrate exposure endpoints collected from BloodCenter
of Wisconsin apheresis run sheets.

Subject Remuneration

Participation in this study was time and travel intensive. At two time points
(baseline and final visits) donors traveled to Marquette University’s campus to have bone
density scans performed. Because of the large geographic catchment area of BCW, study
participants received $50 per visit (no more than $100 total) to cover travel costs (Figure
IV). Additionally, participants were offered full body composition analysis reports (at the
end of the study only) upon request. Throughout the study donors were asked to comply
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with many guidelines including blood donation types, blood donation frequency, fracture
reporting, questionnaires, and study visits. Study participants were evaluated for protocol
compliance at the time of the final visit. Compliance with all of the study’s guidelines
and completion of all study visits resulted in payment of $100 and $250 by check for no
apheresis and apheresis groups, respectively. Total remuneration did not exceed $200 for
donors in the control group and $350 for donors in the apheresis group. Compensation
was not tied to blood donation, but solely for the clinical assessment and completing
research study protocol(s). Please refer to the Final Appointment Letter (Appendix 7).
To proactively address any issues that may arise between the voluntary attribute
of the derived blood component products and study participation, the research team
contacted the FDA’s Center for Biologics Evaluation and Research (CBER) Office in
February 2016. The remuneration plan outlined above was presented alongside the open
question as to whether or not component products could be labeled as “voluntary units”
(21 CFR 606.121(c)(8)(v) and Compliance Policy Guide 230.150, Blood Donor
Classification). The response received from FDA indicates that this remuneration plan is
acceptable as captured in the attached communication (Appendix 8).
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Figure IV. Participation schematic for ALTRUYST participants including amounts of
subject remuneration based on study completeness.
Statistical Methodology

The hypothesis tested was that high frequency apheresis would cause a decline in
BMD from baseline assessment to follow-up. Specifically, the null hypothesis was that
for men aged 18 - 65 years and otherwise satisfying eligibility criteria, there would be no
difference in the magnitude of change in bone mineral density between a baseline and
follow-up bone mineral density assessment for high frequency apheresis donors (Ho: μX
= 0, where X is change in BMD). The alternate hypothesis was that men aged 18 - 65
years and otherwise satisfying eligibility criteria would experience a decline in BMD
between a baseline and follow-up assessment following one year of high frequency
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apheresis (Ha: μX < 0). The T-test statistic was used to compare change over the one year
period in comparison to zero, or no change. This was a randomized study and the control
group did not donate apheresis blood products during the follow-up period. The null
hypothesis for comparing the treatment group (high frequency apheresis group) to this
control group was that change in BMD was no different between the treatment and
control groups (Ho: μX = μY, where X was change in BMD in the treatment group and Y
was change in the control group). The alternate hypothesis tested was that change in the
treatment group was greater in magnitude than change in the control group (Ha: μX <
μY).
There is natural variation in an individual’s peak BMD (63). This source of
variation plays a role in the derivation of power. NHANES 2009 – 2010 examination data
were used in estimating the mean and standard deviation of total lumbar spine BMD for
men aged 25-50. NHANES is a stratified, multistage probability sample of the civilian
non-institutionalized population of the United States. Data are freely available on the
Centers for Disease Control and Prevention website:
http://www.cdc.gov/nchs/nhanes/nh3data.htm.
The demographic and examination data sets were downloaded from NHANES in
April 2015. Using R, the two data sets were merged using sequence number (seqn) as the
linking variable. Using R studio, females were excluded using the gender variable
(riagendr); men aged <25 or >50 were excluded using the age variable (ridageyr);
Caucasian, non-Hispanic men were selected using the race/ethnicity variable (ridreth1).
Mean (1.054925 gm/cm2) and standard deviation (0.1345117 gm/cm2) of total lumbar
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spine BMD (dxxosbmd) was then computed from the restricted data set. The complete
programming syntax for this procedure is included as [Appendix 9].

PRECISION ASSESSMENT

An in vivo precision assessment of the individual technologist performing all bone
mineral density scans in this project was performed in August of 2015 (lumbar spine) and
again in July 2017 (total hip). Precision assessment was performed per ISCD guidelines
(64). In summary, 15 patients were scanned on the same DXA machine thrice with
repositioning in between assessments. Eligible participants were male, between 18 and 65
years of age, generally healthy and otherwise eligible for the research study. Precision
assessment was performed on the lumbar spine (L1 – L4, Table V) and at the total hip
(Table VI). Volunteers were offered full body composition analysis (optional). If a full
body scan was performed, it was conducted before the serial L1-L4 and total hip
measurements. Repositioning entailed removal of the leg support block, sitting followed
by standing, several paces of normal walking, and then complete repositioning of the
volunteer. All scans contributing to the precision assessment were performed within two
weeks of each other.
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Subject

1st Scan

2nd Scan

3rd Scan

SD

SD2

LSC 1

1.221

1.225

1.221

0.00231

0.00001

LSC 2

1.532

1.522

1.524

0.00529

0.00003

LSC 3

1.153

1.153

1.171

0.01039

0.00011

LSC 4

1.118

1.122

1.103

0.01002

0.00010

LSC 5

0.908

0.918

0.902

0.00808

0.00007

LSC 6

1.217

1.217

1.219

0.00115

0.00000

LSC 7

1.106

1.101

1.100

0.00321

0.00001

LSC 8

0.979

0.970

0.971

0.00493

0.00002

LSC 9

1.226

1.227

1.225

0.00100

0.00000

LSC 10

1.182

1.187

1.166

0.01097

0.00012

LSC 11

1.253

1.238

1.239

0.00839

0.00007

LSC 12

1.433

1.435

1.436

0.00153

0.00000

LSC 13

1.104

1.123

1.109

0.00985

0.00010

LSC 14

1.104

1.098

1.08

0.01249

0.00016

LSC 15

1.002

0.994

0.990

0.00611

0.00004

Sum

0.00083

Sum/n

0.00006

RMSD

0.00743

Table V. Serial mean lumbar spine bone density values (g/cm2) for L1 – L4 in 15 male
subjects scanned in August 2015 with repositioning between scans. SD = standard
deviation; n = 15; RMSD = root mean square deviation, or, precision error.
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Subject

1st Scan

2nd Scan

3rd Scan

SD

SD2

LSC 16

1.160

1.158

1.149

0.005859

0.000034

LSC 17

1.195

1.204

1.192

0.006245

0.000039

LSC 18

1.002

1.008

0.998

0.005033

0.000025

LSC 19

0.955

0.956

0.940

0.008963

0.000080

LSC 20

1.093

1.102

1.090

0.006245

0.000039

LSC 21

1.023

1.015

1.022

0.004359

0.000019

LSC 22

1.236

1.201

1.234

0.019655

0.000386

LSC 23

0.987

0.990

1.001

0.007371

0.000054

LSC 24

1.136

1.152

1.144

0.008

0.000064

LSC 25

1.118

1.121

1.110

0.005686

0.000032

LSC 26

1.268

1.267

1.271

0.002082

0.000004

LSC 27

0.886

0.890

0.898

0.00611

0.000037

LSC 28

0.998

1.001

0.995

0.003

0.000009

LSC 29

1.100

1.097

1.107

0.005132

0.000026

LSC 30

1.034

1.030

1.028

0.003055

0.000009

Sum

0.000860

Sum/n

0.000045

RMSD

0.006708

Table VI. Serial mean femoral neck bone density values (g/cm2) for the total hip in 15
male subjects scanned July – September 2017 with repositioning between scans. SD =
standard deviation; n = 15; RMSD = root mean square deviation, or, precision error.

POWER COMPUTATIONS

Step 1 involved simulating the distribution of T under the null hypothesis (H0).
First, population parameters for μ (population mean), σ (population standard deviation),
and ρ (correlation) were set. Next, a covariance matrix for each group (exposure and
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control) was established. We are not able to make the assumption that the two variables
being measured, Xbefore and Xafter, or Ybefore and Yafter, are independent. Therefore,
simulation occurred for various sample sizes with 10,000 iterations of a multivariate,
normal variable random sampling method. Average change and standard deviation in
bone mineral density for exposure and control were calculated. α was set to 0.05 and
distributions of test statistics were visually inspected through histogram. The
programming code was developed and executed in R: a language and environment for
statistical computing (65) and is provided as [Appendix 10].
Step 2 involved simulating the distribution T under Ha. μ was set to the
population mean for all time points except for a 3% reduction in the exposure group. σ
was set to be the same for both groups at all time points. ρ was set to be equal to ρ as for
H0. The same covariance matrix was used for each group. Simulation also occurred with
10,000 iterations of a multivariate, normal variable random sampling method. Average
change and standard deviation were calculated. α was set to 0.05 and data were visually
inspected through histogram. The programming code was developed and executed in R
(65) and is provided as Appendix 10.
Step 3 involved determining the critical value. In R, the quantile function was
used to derive the critical value where the probability of the test statistic is greater than
the critical value under H0. This value is equal to 1 – α.
Step 4 involved computing power. In R, the power was computed by adding the
values of the test statistic under Ha where this value was greater than the critical value.
This sum was then divided by the number of simulated iterations.
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Power simulations were conducted for a two measurement design: a baseline
assessment of BMD and an assessment after one year of treatment (apheresis) or control
(no apheresis). Mean and standard deviation of lumbar spine BMD were calculated from
NHANES III as above and a 3% decline in BMD in the exposure group was selected as
the primary outcome. Using this approach, power was calculated for various sample sizes
and ρ = 0.1, 0.5, 0.9, 0.925, and 0.95. Because healthy men comprising this cohort have
no change in BMD over a one year period on average (Looker, Melton et al. 2010), it was
assumed that there would be a high degree of correlation between baseline and follow-up
assessments (e.g. ρ = 0.99). The primary sources of variation in this model would be the
technologist’s LSC and the variance of change in BMD for the exposure group.

Attrition and Randomization

Studies in blood donor populations with very similar interventions demonstrate
highly varied degrees of attrition (e.g. (66, 67)). In the present study, all enrolled donors
were recruited from a pool of donors willing to undergo high frequency apheresis.
Nevertheless, it was expected that donors randomized to continue with apheresis as
planned would demonstrate a higher rate of attrition relative to those randomized to
forgoing apheresis for the one year follow-up period. To preserve this study’s analytic
sample size, unequal attrition estimates were used to compute required enrollment sample
sizes.
In conclusion, an estimated 80% power was achieved with approximately 20
subjects analyzed as treatment and 15 analyzed as controls. It was expected that donors
randomized to apheresis would be more likely to undergo attrition. If one in five donors
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randomized to treatment dropped out of the study (i.e. 20% attrition), then the probability
of preserving the desired analytic sample size in this group was approximately 91% when
28 donors are enrolled. The probability of preserving the desired analytic sample size in
the control group, estimated to experience 5% attrition, was approximately 95% when 17
donors were enrolled. Total enrollment cohort size in this scenario was n = 45 (28 + 17 =
45). With approximately two thirds of the randomized cohort being assigned to treatment
(62%), a 2:1 randomization was used. A projected subject workflow with numbers is
provided in Figure V.

Assessed for Eligibility (n = 80)
Not Enrolled (n = 33)
• risk factor (n = 5)
• unwilling to donate (n = 28)
Enrolled (n = 47)

Excluded (n = 3)
• BMD <-2.0 (n = 2)
• BMD > 2.0 (n = 1)

CONTROL (n = 17)

APHERESIS (n = 27)

Lost to Follow-Up (n = 2)

Lost to Follow-Up (n = 2)

Did not Comply (n = 0)

Did not Comply (n = 5)
ANALYZED (n = 15)

ANALYZED (n = 20)

Figure V. Projected subject workflow for ALTRUYST study showing effects of
anticipated subject attrition rates and preservation of analytic sample size.

Human Subjects Considerations

This study was submitted to local Institutional Review Board (IRB) review prior
to any human subjects participation. Informed consent was required due to radiation
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exposure associated with DXA and the randomized study design. There was no direct
benefit to subjects who participated in this study other than remuneration for each DXA
visit and study compliance, and, full body composition reports from DXA after study
completion. If a participant was eligible based on the screening questionnaire, then there
was a minimum of one suite of DXA scans performed at baseline. For participants who
completed the study, a total of two suites of DXA scans were performed (one at baseline
and one at follow-up). Each completed DXA assessment resulted in payment of $50 to
the participant to remunerate costs associated with time and travel. Total remuneration
for two suites of DXA scans was $100. In addition, participants who complied with the
protocol intervention into which they were randomized (20 – 26 apheresis procedures, or
no apheresis procedures during the follow-up) received additional compensation at the
end of the study (equal to $100 or $250). The most an individual participant received as
part of their participation in this study was $200 or $350, based on randomization and
compliance. There was no remuneration granted to participants for any blood donation
activities – these were all voluntary donations per FDA guidance.
Women were not included in this study due to a high degree of variability in bone
density both across age strata and over the life course (Looker, Melton et al. 2010).
Because all participants were male, there was no need to assess child-bearing status
before DXA in this cohort. The inclusion of racial minorities was not precluded;
however, powering the study to detect between-race interactions was untenable based on
the low representativeness of various racial groups in the blood donor population.
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Potential Risks

Potential risks for participation in this study were associated with risks of
venipuncture, exposure to radiation from DXA, and loss of confidentiality. Risks of
venipuncture were the same as those for routine apheresis and whole blood donation
which eligible subjects regularly accept. These risks were presented to volunteer blood
donors at the time of every donation. This risk was considered minimal and was
discussed in the informed consent document signed by all participants.
Pencil beam BMD scanners employ a narrow (2-3 mm) x-ray beam with a single
detector, while fan beam scanners use broader, fan shaped beams. The original version
utilizes an array of multiple detectors in a single pass while the newer, narrow angle fan
beam scanners have a smaller detector array and perform multiple, overlapping passes
(68). Overall, fan beam scanners offer shorter scan times, better resolution, and slightly
higher radiation doses than pencil beam scanners. DXA measurement was performed
using fan beam scanners exclusively in this study.
Although DXA conveys a relatively low radiation dose to the patient, the areas
irradiated include sensitive organs such as the bone marrow, and in some instances,
reproductive organs. Radiation dose is contingent upon the method and mode of delivery
and the significance of the exposure depends upon the body part irradiated. The
Radiological Society of North America (69) provides a comparison of radiation exposure
from various procedures to natural environmental exposure. A typical whole body DXA
scan is equivalent to three hours of natural background radiation. Overall, results show
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that DXA is a low dose examination compared to other ionizing radiation procedures
such as standard radiographs (70). Radiation exposure data are summarized in Table VII.

TYPE OF EXPOSURE

EFFECTIVE
RADIATION DOSE
(μSv)

Mammogram (70)

450

Air Flight JFK to ORD
(71)

390

Chest X-Ray (70, 72)

100

Daily Natural Exposure
(70)
Lumbar Spine DXA (73,
74)
Femoral Neck DXA (73,
74)

0.7

Whole Body DXA (72, 74)

3

All 5 DXA Scans

5.8

8

0.7

Table VII. Effective radiation dose for select natural
exposures and exposures associated with dual energy
x-ray absorptiometry (DXA) bone scans.

Protection Against Study Risks

While the radiation dose is low, there still may be concern with reproductive
organ exposure. Any attempt at shielding has the potential to compromise scan results.
Reproductive organ exposure to scattered radiation during the lumbar spine scan does
occur, and exposure during hip scans is dependent on the size of the scan field (75).
Although DXA scans deliver low radiation doses to patients compared to general-purpose

51

radiographic systems, technical competency is necessary to minimize unnecessary
exposure and to produce accurate results. Improper patient positioning may result in
unintended and unnecessary exposure to the patient as well as staff. The scan operator
was therefore appropriately trained to perform scans safely, accurately, and reliably. The
DXA facility performed quality control and precision testing to ensure accuracy and
reproducibility of results (76).
Staff persons involved in this project had extensive experience implementing
clinical studies where confidential information is collected, stored, and utilized for
research purposes. All original documentation were assembled in donor records
maintained in secure locations at BloodCenter of Wisconsin and Marquette University
facilities. Information on enrolled donors were identified by a unique, anonymized
subject ID for the purposes of anonymity and laboratory testing. DXA measurement data
remained in a secure-access room, on the access-restricted hard drive, at Marquette
University or in the paper-based chart assembled at BloodCenter of Wisconsin. The only
people with access to identifiable information in this study were CITI certified and listed
as personnel on the IRB-approved protocol.
Due to the limited interventional nature of this study (randomization and DXA)
reporting requirements were limited to abnormal BMD discovered through DXA, losses
of confidentiality, and adverse outcomes associated with venipuncture. All abnormal
DXA results from this study [BMD Z-score <(-2.0) or >(2.0)] were reviewed by this
study’s Medical Monitor. The recommendation to seek personal medical attention in the
form of an IRB-approved letter was provided to subjects. These reports were generated
on behalf of the Medical Monitor, shared with all study personnel, and reported to the
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IRB as required. Adverse events associated with venipuncture were addressed per local
protocol and reported to the IRB as required.
This study’s Medical Monitor was an endocrinology-trained physician
experienced in the diagnosis and treatment of patients with osteoporosis. Dr. Robert D.
Blank, Chief of Endocrinology, Metabolism, and Clinical Nutrition at the Medical
College of Wisconsin served as the Medical Monitor. This physician reviewed all
abnormal DXA reports and adjudicated adverse findings as needed. Specifically, any
BMD Z-score ≤(-1.9) or ≥(1.9), as determined by the DXA technologist were forwarded
for review by the Medical Monitor. It is likely that upon notification of abnormal BMD,
subjects would be evaluated, and possibly treated, for a bone or metabolism-related
disease by their physician, thus affecting follow-up BMD measurements and confounding
study results. Therefore, all subjects were asked as part of the risk assessment survey
whether or not they are currently or have ever taken medications that are used in the
treatment of low BMD. These data were used first to screen for eligibility and later upon
data analysis. All subjects were given the results of their DXA results upon request, but
only after completing their participation in the study to help mitigate potential
modifications to behavior during the study.

Statistical Analysis

The distributions of continuous and ordinal variables at baseline were compared
using the t-test statistic and Fisher’s exact test, respectively. The primary outcome was
defined a priori as change in lumbar spine BMD and the secondary outcome was change
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in total hip BMD. The intention to treat analysis included all subjects who completed
follow-up. A compliance analysis was also performed that included only those subjects
who complied with the criteria of their randomization. Multivariable logistic regression
was performed as an exploratory analysis using the questionnaire, laboratory, baseline
BMD data, and, treatment arm as predictors of change in bone density exceeding the
LSC. Bilirubin, alkaline phosphatase, and anion gap were log transformed to achieve
normal distributions. Automated stepwise backwards elimination was subsequently
performed to identify significant predictors of both positive and negative response. The
programming code was developed and executed in R: a language and environment for
statistical computing (65) and is provided as [Appendix 11].

TIMELINE

The projected timeline for the ALTRUYST trial is presented in Table VIII.
Activity

Period

Power Computation

Spring 2015

DXA Precision Assessment

Summer 2015

Finalize Proposal

Fall 2015

Clinical Trials.gov Registration

Winter 2015

IRB Submission

Spring 2016

Enroll Subjects

Summer 2016

Enroll Subjects & Follow-Up

Fall 2016

Follow-Up

Spring 2017

Final Visits

Summer 2017

Final Visits & Analysis & Publication

Fall 2017

Table VIII. ALTRUYST project timeline.
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CHAPTER FOUR: ALTRUYST Results

Human Subjects Approvals and Enrollment

BloodCenter of Wisconsin Quality Support Services supported the application for
a determination that the proposed study remuneration plan was compliant with 21 CFR
606.121(c)(8)(v) and local Compliance Guide 230.150 in February, 2016. The Blood and
Tissue Compliance Branch (BTCB) at the US Food and Drug Administration (FDA)
acknowledged that these requirements had been met and that the proposed donor
incentive did not constitute monetary payment (Appendix 8) allowing labeling and
transfusion of derived component blood products as “Volunteer Blood Donor”.
Thereafter, the study team sought ceded IRB approval from the Marquette University
Institutional Review Board (IRB). The Inter-Institutional Liaison for Human Research
Protections approved the request in February, 2016 (Appendix 12). The study was then
submitted to the Medical College of Wisconsin (MCW) IRB for approval. The
Department of Physiology at MCW provided an attestation that the project had scientific
merit, used procedures consistent with sound research design, and was likely to yield the
expected knowledge; and that the proposal was a complete and coherent one on April 5,
2016 (Appendix 12). Radiation verification and approval from the Radiation Safety
Office at MCW was received on April 28, 2016 (Appendix 13). The study was reviewed
by Institutional Review Board #3 on April 26, 2016. The Committee determined that the
study met all criteria under 21 CFR 56.111 and provided an approval notice (Appendix
14). IRB-approved screening methods commenced and the first subject was enrolled per
protocol on May 18, 2016 and the final subject was enrolled on January 28, 2017. Figure
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VI shows 100%, 75%, and 50% of enrollment goals with actual enrollment numbers
(black line) and the number of eligible enrollees (dashed line) superimposed over the
projected 100% (green), 75% (yellow) and 50% (red) cumulative accrual numbers.

Figure VI. Cumulative enrollment chart showing 100%, 75%, and 50%
enrollment goals with actual and eligible numbers superimposed.

Enrollment and Analytic Samples

Among 120 volunteer blood donors assessed for eligibility, 58 enrolled in the
study (Figure VII). Seven enrollees were subsequently excluded for having a bone
density Z score <-2.0 or > 2.0 at enrollment. Three additional subjects were excluded for
having previously undergone apheresis more than five times and one subject was
excluded for weighing more than 300 pounds. Ultimately, 32 subjects were randomized
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to apheresis and 15 to the control arm. Approximately 20% of subjects from the apheresis
arm were not available at follow-up: two subjects voluntarily withdrew from the study
(6%) and four subjects were lost to follow-up (11%). All subjects in the control arm were
available at follow-up.

Figure VII. Enrollment schematic showing recruitment, enrollment, ineligibility, and
losses to follow-up for the ALTRUYST trial. ITT = Intention to Treat
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Baseline Demographics, Laboratory Test Results, and Donation History

The distributions of baseline characteristics are provided in Figure VIII. A
peripheral blood sample was not available for four participants. Bilirubin, alkaline
phosphatase, and anion gap were log transformed for all donors to achieve normal
distributions (Figure IX). Male, adult testosterone concentrations were below the lower
normal range cutoff in three donors: two in the treatment arm and one in the control arm.
Mean age at enrollment was 43.8 years (SD = 13.5) with one donor (2%) reporting
African American race and another (2%) reporting Hispanic ethnicity (Table IX). Mean
height (p=0.89), weight (p=0.25), and body mass index (BMI) (p=0.38) were no different
between study arms. Baseline laboratory parameters were similar between groups
(p=0.14-0.97), as were the number of previous whole blood (median = 5, p=0.73) and
apheresis (median = 3, p=0.49) donations. Though lumbar spine bone density was not
different between study arms (p=0.26), bone density at the total hip was, on average,
0.107 g/cm2 higher among those donors randomized to the apheresis arm (p=0.03) (Table
IX). The lower limit of the reference range for testosterone is 300ng/dL and three
individuals were below that value at enrollment. The only individual among these three
who experienced clinically meaningful change in BMD was a 25 year old male in the
control group who experienced a 4.3% decline in total hip BMD and 2.2% decline at the
L-spine. The only other laboratory value out of the normal reference range was anion
gap: value 18 mmol/L (ref range 7 - 15).
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Figure VIII. Distributions of variables at baseline (N=37).
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Figure IX. Effect of log-transforming anion gap, alkaline phosphatase, and bilirubin on
their distributions (N = 37).
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Table IX. Descriptive characteristics of ALTRUYST blood donors at enrollment.
Apheresis
26

No Apheresis
15

Total
41

p
-

DEMOGRAPHICS
42.6 (13.1)
25 (96%)
1 (4%)

45.9 (14.3)
15 (100%)
0 (0%)

43.8 (13.5)
44 (98%)
1 (2%)

0.46
-

Height (inches)
Weight (pounds)
Body Composition (% body fat)

ANTHROPOMETRICS1
70.4 (2.4)
70.2 (3.2)
203.2 (32.2)
191.7 (29.0)
28.9 (4.7)
27.5 (5.0)

70.3 (2.7)
199.0 (31.2)
28.4 (4.8)

0.89
0.25
0.38

Serum Sodium (mmol/L)
Serum Potassium (mmol/L)
Serum Chloride (mmol/L)
Serum Carbon Dioxide (mmol/L)
Anion Gap (mmol/L)
Serum Urea Nitrogen (mg/dL)
Serum Creatinine (mg/dL)
Serum Glucose (mg/dL)
Alkaline Phosphatase (U/L)
Aspartate Aminotransferase (U/L)
Alanine Aminotransferase (U/L)
Serum Calcium (mg/dL)
Serum Inorganic Phosphorous (mg/dL)
Serum Total Protein (g/dL)
Serum Albumin (g/dL)
Serum Total Bilirubin (mg/dL)
Adult Male Testosterone (ng/dL)

LABORATORY DATA1
143 (2.3)
142 (2.1)
4.5 (0.3)
4.7 (0.3)
101 (1.9)
100 (3.0)
22 (1.5)
21 (1.5)
20 (2.2)
20 (1.8)
16 (3.7)
15 (5.3)
1.00 (0.14)
0.99 (0.15)
97 (16)
101 (25)
67 (15)
75 (22)
26 (8)
27 (4)
25 (12)
25 (7)
9.7 (0.4)
9.7 (0.5)
3.3 (0.5)
3.5 (0.4)
7.2 (0.4)
7.4 (0.5)
4.6 (0.3)
4.7 (0.3)
0.6 (0.4)
0.6 (0.3)
520 (198)
515 (202)

143 (2.3)
4.6 (0.3)
101 (2.3)
22 (1.5)
20 (2.0)
15 (4.2)
1.00 (0.14)
98 (19)
70 (18)
26 (7)
25 (10)
9.7 (0.4)
3.4 (0.5)
7.3 (0.5)
4.6 (0.3)
0.6 (0.3)
518 (196)

0.24
0.38
0.37
0.19
0.34
0.80
0.83
0.66
0.33
0.53
0.97
0.93
0.14
0.39
0.49
0.95
0.94

5
3

0.73
0.49

1.197 (0.127)
1.094 (0.153)

0.26
0.03

n
Age (mean, SD)
Caucasian (n, %)
Latino/Hispanic (n, %)

Whole Blood (n)
Apheresis (n)
Lumbar Spine (g/cm2)
Total Hip (g/cm2)
1
mean (SD)
2
median

PREVIOUS BLOOD DONATIONS2
6
4
3
3
BONE DENSITY1
1.214 (0.130)
1.168 (0.120)
1.133 (0.149)
1.026 (0.140)

63

Blood Donations During ALTRUYST

ALTRUYST donors made a total of 534 combined blood donations during the
one year study period (Figure X). All 15 (100%) donors randomized to the control arm
complied with the protocol (three made zero donations, Figure X), whereas five (19%)
apheresis donors did not achieve a minimum of 20 apheresis donations (Figure X). The
most common apheresis donation type was a double platelet donation with mean interval
between donations of 17.8 days (Table X). Donors in the apheresis arm experienced a
median of 20 apheresis blood donations during the one year study period with the amount
of citrate exposure by donation type ranging from 164mL – 657mL (Table X). The
duration of each donation ranged from just under 30 minutes to more than two hours in
length.

Table X. Apheresis collection and anticoagulant exposure characteristics for donors
randomized to the treatment arm (high frequency apheresis) during the ALTRUYST
trial.
Single

Double

Triple

Number of Platelet Apheresis
110
320
62
Donations
Concurrent Plasma Collection n
0 (0%)
4 (1%) 0 (0%)
(%)
Collection
Mean (SD) Collection Time
57.6
89.4
97.1
Information
(minutes)
(21.8)
(23.3)
(24.9)
Mean (SD) Inter-Donation Interval
17.8 (14.7)
(days)
Type of Anticoagulant
ACD-A1
Anticoagulant
Mean (SD) Volume (mL) AC Infused
299
469
498
Exposure
per Procedure
(104)
(111)
(117)
1
ACD-A = anticoagulant citrate dextrose solution, solution A (2.13% free citrate ion)
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Figure X. Cleveland dot plot of donations (solid dots, n = 543) and deferrals (open dots,
n = 38) from donors during the ALTRUYST study. The top panel shows donors
randomized to apheresis and the bottom panel shows donors randomized to no apheresis
(i.e. whole blood only). Each donor is represented as a row with the number of successful
donations made during the study shown to the left.
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Primary Outcome

Lumbar spine bone mineral density did not change among donors in the control
arm after one year of participation (1.168 g/cm2 at enrollment, 1.170 g/cm2 at follow-up,
mean change = -0.002 g/cm2, 95%CI [-0.020, 0.016], p=0.16), nor did it change among
donors in the apheresis arm (1.214 g/ cm2 at enrollment, 1.213 g/cm2 at follow-up, mean
change = 0.007 g/cm2, 95%CI [-0.005, 0.018], p=0.24) (Figure XI). Tests for differences
in proportions of donors with change in BMD exceeding the least significant change
(LSC) at the lumbar spine (0.00743 ±0.02058g/cm2) between the apheresis and control
arms in either a positive [apheresis 13 (50%), control 5 (33%), p=0.84] or negative
direction [apheresis 8 (31%), control 6 (40%)] were statistically non-significant (p=0.87)
(Figure XII). Performing the analysis with only those donors who complied with the
protocol (i.e. apheresis donors making ≥20 apheresis donations) did not meaningfully
alter these results.
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LUMBAR SPINE

Change in Bone Mineral Density (g/cm2)

0.06

0.03

0.00

-0.03

-0.06

CONTROL

APHERESIS

Figure XI. Boxplot showing change in bone mineral density at
the lumbar spine for control (left, n = 15, mean change=-0.002
g/cm2, 95% CI [-0.020, 0.016], p=0.78) and apheresis (right, n
= 26, mean change=0.007 g/cm2, CI [-0.005, 0.018], p=0.24)
donors in the ALTRUYST trial. Diamonds indicate mean
values; median change is represented as the central horizontal
bar within the interquartile range box. The blue shaded region
indicates the least significant change for the technologist.
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60
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p=0.25
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Figure XII. Proportion of subjects experiencing a decrease (left) (LS = lumbar spine,
apheresis 8 (31%), control 6 (40%)) or increase (LS right, apheresis 13 (50%), control 5
(33%)) in BMD exceeding the least significant change. Proportion of subjects
experiencing a decrease (left) (TH = total hip, apheresis 11 (42%), control 3 (20%) or
increase (LS right, apheresis 6 (23%), control 6 (40%)) in BMD exceeding the least
significant change for LS and TH. Donors in the apheresis arm are in light blue and
donors in the control arm are in dark blue.

Secondary Outcomes

Change in mean BMD at the total hip was not statistically significant for control
donors (1.026 g/cm2 at enrollment, 1.028 g/cm2 at follow-up, mean change = 0.002
g/cm2, CI [-0.006, 0.009], p=0.63) or apheresis donors (1.133 g/cm2 at enrollment, 1.129
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g/cm2 at follow-up, mean change = -0.004 g/cm2, CI [-0.10, 0.002], p=0.16) (Figure
XIII). Proportional increases [apheresis 6 (23%), control 6 (40%), p=0.25] and decreases
[apheresis 11 (42%), control 3 (20%)] were also not significantly different (p=0.15) at the
total hip (LSC=0.00671±0.01859g/cm2) (Figure XII). Performing the analysis with only
those donors who complied with the protocol (i.e. apheresis donors making ≥20 apheresis
donations) did not meaningfully alter these results.
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TOTAL HIP

Change in Bone Mineral Density (g/cm2)
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Figure XIII. Boxplot showing change in bone mineral density
at the total hip for control (left, n = 15, mean change=0.002
g/cm2, 95% CI [-0.006, 0.009], p=0.63) and apheresis (right, n
= 26, mean change-=0.004 g/cm2, CI [-0.010, 0.002], p=0.16)
donors in the ALTRUYST trial. Diamonds indicate mean
values; median change is represented as the central horizontal
bar within the box representing the interquartile range. The
blue shaded region illustrates the least significant change for
the technologist.

Mean femoral neck bone mineral density did not change among donors in the
control arm after one year of participation (0.969 g/cm2 at enrollment, 0.969 g/cm2 at
follow-up, mean change = 0.000 g/cm2, 95%CI [-0.009, 0.009], p=0.63), nor did it
change among donors in the apheresis arm (1.094 g/cm2 at enrollment, 1.093 g/cm2 at
follow-up, mean change = -0.001 g/cm2, 95%CI [-0.010, 0.007], p=0.74) (Figure XII).
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Mean trabecular bone score was 1.388 (SD = 0.098) in the control group at enrollment
and did not significantly change over the one year study period (1.406 (SD = 0.112) at
follow-up, mean change = -0.003, 95%CI [-0.024-0.019], p=0.79). Donors in the
apheresis arm had a mean trabecular bone score at enrollment of 1.474 (SD = 0.105) and
it did not change over the one year study period (1.475 (SD = 0.133) at follow-up, mean
change = 0.001, 95%CI [-0.022, 0.024], p=0.92).

Multivariable Logistic Regression

Multivariable logistic regression with change exceeding the LSC in both positive
(gain in BMD) and negative (loss of BMD) directions using automated stepwise
backwards elimination did not identify baseline covariates that were significantly
associated with either outcome (Table XI). This was an exploratory analysis as the study
was not powered to identify significant predictors. The regression took the general form:
logit[pr(Y=1)] = β0 + β1 (apheresis) + β2 (age) + β3 (risk factors=1) + β4 (risk
factors=2) + β5 (risk factors=3) + β6 (risk factors=1) + β7 (family history=1) + β8
(family history=2) + β9 (family history=3)+ β10 (health conditions=1) + β11 (health
conditions=2) + β12 (medication use=1) + β13 (diet=3) + β14 (diet=4) + β15 (diet=5)
+ β16 (diet=6) + β17 (diet=7) + β18 (medication use=2) + β19 (BMI) + β20
(pre_(site)) + β21 (Na) + β22 (K) + β23 (Cl) + β24 (CO2) + β25 (anion gap) + β26
(urea) + β27 (creatinine) + β28 (glucose) + β29 (alkaline phosphatase) + β30 (AST) +
β31 (ALT) + β32 (Ca) + β33 (P) + β34 (protein) + β35 (albumin) + β36 (bilirubin) +
β37 (testosterone)
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Table XI. Results of exploratory multivariable logistic regression analysis with change
in bone mineral density as the outcome [coefficient (p value)].
Negative Change
Positive Change
Lumbar
Total
Lumbar
Total
Spine
Hip
Spine
Hip
Apheresis versus No
0.49 (0.04)
1.64 (0.36)
0.48 (0.19) -0.80 (0.53)
Apheresis
Age
-0.03 (0.03) 0.00 (0.92)
0.04 (0.09)
0.02 (0.53)
Risk Factors = 1
-0.54 (0.06) -0.25 (0.79) -0.25 (0.38) 0.06 (0.94)
Risk Factors = 2
-0.15 (0.22) 1.28 (0.54) -0.23 (0.44) -1.17 (0.52)
Risk Factors = 3
-0.65 (0.09) 0.33 (0.87) -0.83 (0.24) -0.17 (0.92)
Risk Factors = 4
-2.70 (0.03) 2.57 (0.54)
2.79 (0.11) -2.59 (0.49)
Family Risk Factors = 1
-0.27 (0.17) 0.70 (0.69) -0.95 (0.17) -1.78 (0.36)
Family Risk Factors = 2
-0.96 (0.04) 0.33 (0.81) -0.11 (0.71) -1.51 (0.34)
Family Risk Factors = 3
-1.09 (0.07) 1.56 (0.64)
0.18 (0.76) -4.15 (0.30)
Health Conditions = 1
1.13 (0.03)
0.86 (0.58)
0.06 (0.83) -0.12 (0.92)
Health Conditions = 2
2.99 (0.05) -0.52 (0.92) 1.78 (0.26)
3.30 (0.51)
Medication Use = 1
-0.53 (0.09) -0.76 (0.64) -0.95 (0.16) 0.02 (0.99)
Diet = 3
0.31 (0.11)
0.71 (0.65) -0.04 (0.87) -0.05 (0.97)
Diet = 4
-0.11 (0.36) 0.57 (0.75)
0.55 (0.27) -0.09 (0.95)
Diet = 5
0.91 (0.04) -0.29 (0.81) -1.69 (0.08) -0.47 (0.67)
Diet = 6
1.40 (0.03) -0.85 (0.60) -1.16 (0.14) 1.45 (0.39)
Diet = 7
5.05 (0.02) -0.97 (0.77) -1.05 (0.31) 2.58 (0.45)
Body Mass Index
0.04 (0.07) -0.06 (0.61) 0.01 (0.75)
0.11 (0.38)
Baseline BMD
4.54 (0.03) -4.69 (0.50) -5.65 (0.08) 4.21 (0.48)
Serum Sodium
-0.11 (0.11) -0.62 (0.41) -0.30 (0.14) 0.44 (0.47)
Serum Potassium
0.60 (0.08) -0.59 (0.75) -2.16 (0.08) -0.35 (0.82)
Serum Chloride
-0.15 (0.10) 0.54 (0.46)
0.11 (0.43) -0.63 (0.37)
Serum Carbon Dioxide
-0.12 (0.07) 0.06 (0.87)
0.29 (0.11)
0.10 (0.77)
Serum Urea Nitrogen
0.15 (0.02) -0.05 (0.59) -0.12 (0.09) 0.05 (0.55)
Serum Creatinine
-4.15 (0.03) 4.25 (0.60)
2.44 (0.17) -3.84 (0.58)
Serum Glucose
0.00 (0.40)
0.02 (0.50) -0.02 (0.14) -0.05 (0.25)
Alkaline Phosphatase
-0.01 (0.13) 0.02 (0.50)
0.02 (0.18)
0.00 (0.98)
Aspartate Aminotransferase
0.01 (0.18)
0.08 (0.53)
0.03 (0.23) -0.03 (0.74)
Alanine Aminotransferase
-0.06 (0.03) 0.04 (0.65)
0.08 (0.09) -0.04 (0.60)
Serum Calcium
-0.51 (0.10) 0.56 (0.83)
0.37 (0.40) -2.51 (0.39)
Serum Inorganic
-0.02 (0.67) 0.56 (0.63) -0.40 (0.19) -0.39 (0.69)
Phosphorous
Serum Total Protein
-0.24 (0.28) -0.58 (0.75) -2.24 (0.11) 0.23 (0.88)
Serum Albumin
-0.51 (0.18) 0.68 (0.83)
4.42 (0.07)
1.79 (0.55)
Serum Total Bilirubin
-0.15 (0.22) 1.06 (0.62) -1.55 (0.08) -2.09 (0.36)
Adult Male Testosterone
0.00 (0.04)
0.00 (0.65)
0.00 (0.85)
0.00 (0.81)
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Dual-Energy X-ray Absorptiometry Calibration

Appendix 15 shows the quality assurance data for the period of image acquisition
(May 1, 2016 – February 1, 2018). During this period, 597 phantom scans were
performed per protocol. A phantom scan was performed within the 48 hour period
preceding every ALTRUYST scan. Density of the phantom is 1.497, 0.995, and 0.497
g/cm2 at the high, medium, and low bands, respectively. The percent coefficient of
variation was 0.3%, 0.6%, and 1.3% for high, medium, and low BMD regions during the
period of scan acquisition, respectively. Overall BMD precision was 0.24% (Appendix
15). The machine was not moved during the project period, and, all routine service and
maintenance were performed per manufacture specifications.

Conclusion
ALTRUYST was a prospective, longitudinal, randomized controlled trial
evaluating the role of high frequency apheresis blood donation on change in BMD. There
were no significant alterations to BMD at the lumbar spine or total hip. Therefore, the
null hypothesis that high frequency apheresis blood donation does not cause significant
declines in BMD after a one year follow-up period cannot be rejected. Analyses of
secondary outcome measures indicate that there were no significant changes in mean
femoral neck BMD, nor trabecular bone scores. Multivariable logistic regression was not
able to identify significant predictors of either positive or negative change at any site
measured due to potential lack of statistical power. An analysis of those apheresis donors
who complied with the protocol did not alter these conclusions.
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CHAPTER FIVE: ALTRUYST Discussion

ALTRUYST was a prospective, longitudinal, randomized controlled trial
evaluating the role of high frequency platelet apheresis blood donation on change in
BMD in males and found no significant alterations to BMD at the lumbar spine or total
hip. Previous studies demonstrated a higher prevalence of low BMD among apheresis
donors when compared to non-blood donors (11) or whole blood donor controls, (12)
independent of donor gender or age. One study reported no difference among apheresis
and whole blood donors (13). These conflicting results likely stem from the crosssectional designs employed in these previous investigations. Important determinants of
BMD include genetic (77) and behavioral factors (78) that have been integrated into
previous study designs to varying degrees. Using an individual blood donor as their own
control represents a key feature of ALTRUYST supporting the conclusion that very high
frequency platelet apheresis, and concomitant exposure to large doses of citrate AC, over
a one year period do not induce changes in BMD. Furthermore, BMD of a control group
randomly assigned to no apheresis remained unchanged during the study period,
consistent with large studies of the male US population 18-65 years of age (79).
In the absence of fracture, low BMD is the single best predictor of fracture risk
(64) and the corresponding association is exponential (80). Analysis of more than
140,000 Swedish blood donors over a 23 year period demonstrated no association
between the risk of fracture and, mostly (94-98%), plasma apheresis (56). Plasmapheresis
collections expose donors to a fraction of the AC that platelet apheresis donors receive
(23) and high frequency platelet apheresis donors were not present in the SCANDAT2
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analysis. Donors in the ALTRUYST trial almost exclusively donated platelets by
apheresis (<1% of donations involved concurrent plasma collections) and received an
average of between 300mL (single platelet apheresis) and 500mL (triple collections) of
AC per procedure with an average of 17 days between exposures. Most ALTRUYST
donors in the apheresis arm (21/26, 81%) achieved 20 or more apheresis donations during
the one year study period. No donors in the ALTRUYST study experienced fracture
during the follow-up period. Risk for low trauma fractures among otherwise healthy
males 18-65 years of age is essentially zero,(81, 82) and, ALTRUYST was not powered
using significant change in fracture risk as an outcome. Nevertheless, the finding that the
upper limit of citrate AC exposure, both in terms of dose and frequency, failed to produce
significant alterations to BMD among these donors indicates that current apheresis
collection guidelines are adequate in protecting the bone health of the volunteer blood
donor population and do not likely alter fracture risk in this donor population.
Dual-energy x-ray absorptiometry (DXA) is the industry standard for assessing
bone mineral density and has many strengths relative to other BMD technologies. Access
to large reference databases, including the National Health and Nutrition Examination
Survey, permitted estimation of population mean and standard deviation bone mineral
density values, specifically for the age- and gender-eligible group, before enrolling
subjects in ALTRUYST. This feature of DXA allowed for robust modeling of power and
sample size to occur in advance of the study itself. DXA is also the most accurate way of
measuring BMD. The fact that not all insurance providers cover BMD assessment using
DXA does not impact the decision to employ this as the primary outcome as all scans
were provided to subjects free of charge. However, the acquisition of dual photon
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absorptiometry (DPA) images requires significantly more time, which may have made
recruitment for ALTRUYST challenging. Quantitative computed tomography (CT)
provides three-dimensional images at the lumbar spine and has superior ability to
measure changes in trabecular bone earlier than DXA (83). A lack of large reference
databases for quantitative CT, inferior precision, and effective radiation doses several
orders of magnitude higher than DXA are fundamental drawbacks to using this
technology. Ultimately, the ability for DXA to accurately measure areal BMD at the
lumbar spine and total hip, with minimal costs to subjects in terms of time and comfort,
enriched the overall feasibility of performing this clinical trial.
ALTRUYST was 80% powered to detect a 3% change in bone mineral density
over the one year study period. Though mean bone mineral density was higher in the
ALTRUYST cohort relative to a gender- and age-matched sample of the US population,
this is expected due to a well known “healthy donor effect” where volunteer blood donors
consistently present with health indices superior to population norms (84). Furthermore,
the variability about the measure of central tendency among ALTRUYST donors
indicates that individuals within the cohort were not contributing any outlier effects that
could bias our assessment of the study’s outcomes. This is, in part, due to the fact that
ALTRUYST deliberately excluded individuals with BMD that fell outside of a 95%
population-based estimate of mean BMD (i.e. ±2 standard deviations of Z-score). Seven
individuals enrolled in ALTRUYST met this criterion and required exclusion per
protocol. The higher than anticipated prevalence of abnormal BMD in the enrolled cohort
cannot be explained, other than the possibility that such an observation was spurious. The
exceedingly low dose of radiation these individuals experienced represents another aspect
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of DXA that illustrates its superiority in assessing BMD in clinical studies. Other
limitations of DXA are primarily related to potential sources of error, including
differences observed among the three commercial manufacturers, differences in edge
detection softwares, the need for rigorous quality control across systems when multiple
sites are involved due to differences in x-ray tube or detector functionality, technologistrelated sources of error, and various sources of shift and drift in these finely tuned and
calibrated systems. ALTRUYST was a single-center study that used one GE DXA
instrument, one technologist performed all study scans, and shift and drift were quantified
throughout the period of measurement. These design features represent a strength in the
ALTRUYST study and illustrate the much larger sample sizes that would be required to
perform such a study at multiple centers.
BMD over the life course is largely influenced by heritability. Individual
aberrancies in BMD were accounted for using the exclusion criterion for BMD exceeding
two standard deviations of an age- and gender-matched mean value at enrollment. Family
history of fractures was solicited from participants at enrollment through the use of the
questionnaire. Any familial predisposition to disease of bone and mineral metabolism
were coded as an ordinal variable, where the mean value was one and the median value
was also one, were added into the multivariable logistic regression. This predictor did not
achieve significance for changes either in the positive or negative direction. Further, the
randomized nature of this study ensured that the likelihood of being assigned to either
group was equivalent. Nevertheless, confounding could occur if subjects experienced
changes to other important determinants of BMD including physical activity, diet, and
medication use. In addition to excluding subjects with known diseases of bone and
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mineral metabolism, subjects were deliberately excluded if they were taking medications
known to impact BMD. Upon follow-up assessment, no changes in medication were
noted meaning that any confounding from medication use was absent. Physical activity
did not differ between the two randomized groups, and, changes in physical activity
sufficient to invoke changes in BMD over the one year interval did not occur. The selfreport questionnaire was administered by the investigative team to avoid any nonresponse bias. These design features and observations indicate that the findings of
ALTRUYST are extremely unlikely to have known confounding that could have
impacted the results of the study and though the potential for residual, unmeasured
confounding can never be completely eliminated, the complete lack of any significant
change in any outcome measured suggests that any such effect was minimal if present.
In addition to progressive declines in bone density, microarchitectural
deterioration of bone is a fundamental part of the definition of diseases of reduced BMD
(85, 86). Among these microarchitectural features are the number of trabeculae,
separation between trabeculae, and the density of connections between trabeculae.
Changes in these three dimensional features are associated with increasing bone fragility
and susceptibility to fracture, (14, 87) even when bone density is the same between two
samples. The trabecular bone score (TBS) is an analytic tool that quantifies the extent of
between-pixel differences in x-ray attenuation from dual-energy x-ray absorptiometry
images approximating microarchitectural features of bone. In contrast to alternative
techniques for examining bone microarchitecture, obtaining TBS is non-invasive and
uses standard dual-energy x-ray absorptiometry images of the lumbar spine, making it
ideally suited to quantify microarchitectural changes in healthy volunteers. TBS did not
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change among ALTRUYST donors in the apheresis arm, or among donors in the control
arm. This finding is consistent with previous research showing that the magnitude of
change in TBS is less than that of areal BMD in the spine.(88-90) Findings from
ALTRUYST are also consistent with the observation that TBS remains relatively
unchanged before the age of 45 years (91). Future research examining the potential
anabolic effect of repeated apheresis blood donation among aging women would be an
appropriate setting to explore changes in TBS in addition to BMD.
Apheresis induces the secretion of parathyroid hormone (26, 38, 39) and three
cascading physiologic processes ensue: increased calcium reabsorption in the distal
convoluted tubule, increased intestinal calcium absorption, and increased bone resorption.
Data from ALTRUYST indicate that any increase in bone resorption among apheresis
donors did not alter bone density more than what was defined as clinically meaningful a
priori. Surprisingly, apheresis-induced surges in parathyroid hormone produce renal
calcium loss (35, 92). Absorptive hypercalciuria is associated with increased urinary
calcium loss resulting from increased absorption of calcium in the intestine. The elevated
absorption of calcium can be controlled with ingestion of cellulose phosphate that binds
free calcium in the gut (93). Hypercalciuria is also one of the clinical manifestations of
Bartter’s syndrome where genetic mutations in renal sodium-potassium-chloride cotransporters serve as the etiological foundation for this disease (94) and suggest genetic
modifiers of mineral homeostasis could also contribute to the likelihood of an individual
donor’s response to repeated apheresis. In all cases of hypercalciuria, the formation of
calcium stones (nephrolithiasis) is an associated untoward health outcome. Therefore, the
observation that apheresis donors experience hypercalciuria subsequent to donation

79

invokes the possibility that apheresis could meaningfully increase the risk of
nephrolithiasis among donors. Because the formation of calcium stones is a health
outcome with a relatively long latency, case-control studies could theoretically examine
this possibility if medical records and blood donation records were linked.
Disrupting the production of parathyroid hormone to circumvent the renal
excretion of calcium in apheresis donors could theoretically be achieved by providing
oral or intravenous calcium to supplant the biological stimulus for parathyroid hormone
production (namely, reduced serum ionized calcium). Because citrate administration
occurs at the point of venipuncture, any co-administration of calcium avoids interference
with citrate’s role in providing anticoagulation in the extracorporeal circuit. However,
urinary loss of calcium was not suppressed in a placebo-controlled study where oral
calcium was provided to apheresis donors (31). Furthermore, prophylactic intravenous
calcium fails to abrogate the urinary loss of calcium induced by apheresis (35). It is
therefore likely that urinary calcium loss is an obligatory side effect of apheresis blood
donation. Exogenous 1,25 di-hydroxy-vitamin D increases serum calcium through
intestinal absorption and can indirectly modify the set point of parathyroid hormone (95).
Exposure to citrate AC during apheresis blood donation results in surges of parathyroid
hormone in apheresis blood donors that acutely suppresses serum ionized calcium
concentrations. ALTRUYST deliberately recruited healthy volunteers, naïve to apheresis,
and their laboratory test results at baseline were within expected ranges. Therefore, it is
plausible that high frequency apheresis could have altered the set point of parathyroid
hormone with repeated donation during the study. In addition to altering the set point of
parathyroid hormone, studies among patients with vitamin D deficiency have indicated
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that the kidneys can become more sensitive to parathyroid hormone over time (96). This
observation invokes the complimentary possibility that the body copes with high
frequency apheresis blood donation by altering the exchange of phosphate in the
proximal convoluted tubule and calcium in the distal convoluted tubule of kidney
nephrons. Serial serum samples were not obtained from ALTRUYST participants largely
due to concerns around anticipated upper limits of allowable volume depletion in
volunteer blood donors. The physiological mechanism that permits high frequency
apheresis blood donation without alterations to bone mineral density is a provocative
question and future studies would need to integrate design features that stimulate repeated
surges in parathyroid hormone without losing participants to follow-up whose donation
volumes are in excess of accepted standards.
Secondary hyperparathyroidism is a clinical condition that results in sustained
elevations in parathyroid hormone. Insufficient excretion of phosphate, an inability to
produce 1,25 di-hydroxy vitamin D, vitamin D deficiency, and intestinal malabsorption
are among the causes of secondary hyperparathyroidism and the clinical sequelae include
decreased BMD. Because parathyroid hormone concentrations surge in the 60-90 minute
interval when apheresis is being performed (11, 22, 38, 39), we hypothesized that
frequent, repeated surges in parathyroid hormone from apheresis blood donation could
reduce BMD through osteoclastic osteolysis. One clinical feature of secondary
hyperparathyroidism is the enlargement of the glands themselves (parathyroid gland
hyperplasia) that can be reversed with medication (97), illustrating the ability of the
parathyroid glands to adapt to chronic stress. In contrast to secondary
hyperparathyroidism where parathyroid hormone production is chronically increased, the
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recovery of parathyroid hormone to pre-apheresis levels in donors after 120 minutes (11)
may suggest that the stress of apheresis is insufficient to produce hyperplasia in the
parathyroid glands in apheresis donors. Though high frequency apheresis blood donation
does not induce changes in BMD, the possibility that morphological changes in donor
parathyroid glands do not occur cannot be ruled out.
Understanding how the stimulus for parathyroid hormone secretion is received by
the parathyroid glands could provide another mode for mitigating the large surges in
parathyroid hormone experienced by apheresis blood donors. The calcium-sensing
receptor (CASR) is a membrane spanning protein that plays a central role in maintaining
calcium homeostasis in the blood (37) making it an ideal candidate to consider in the
context of personalized apheresis blood donation. Homozygous lack of function
mutations in the CASR gene cause neonatal severe hyperparathyroidism, an autosomal
dominant heritable disease that can be fatal if the parathyroid gland isn’t removed (98100). Heterozygous lack of function mutations in the CASR gene cause familial
hypocalciuric hypercalcemia resulting in altered bone mineralization and increased
incidence of kidney stones (101-103). These clinically apparent diseases have led to the
careful characterization of the CASR (e.g. (104)), including the assessment of CASR
genotype on calcium. A meta-analysis by He and colleagues (105) found that one or two
serine substitutions at locus 986 of CASR resulted in significantly higher total (0.028;
0.012-0.045, P=0.001) and ionized calcium (0.016; 0.013-0.020, P<0.0001) as compared
to subjects homozygous for alanine. Nevertheless, studies combining clinical outcomes,
such as low bone density and kidney stones, with measurements of extracellular calcium
were not able to consistently show detrimental effects of CASR mutations on these
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measures [e.g. (106)] and it is unlikely that blood collecting agencies would genotype
donor polymorphisms for CASR or other potential determinants of mineral homeostasis
before permitting apheresis blood donation. Furthermore, results from ALTRUYST
indicate that any such efforts would primarily target modest improvements in donor side
effects to citrate exposure and not long term health outcomes.
ALTRUYST deliberately studied male blood donors because they constitute the
vast majority (approximately 80%) of the apheresis blood donor population at
BloodCenter of Wisconsin, with 85% of higher frequency donors (defined as ≥15
apheresis donations within a one year period) also male. Furthermore, the study recruited
donors with no more than five lifetime apheresis donations so as to avoid any potential
biological adaptation that may occur with repeated exposure to citrate AC. Though we
report no change in bone mineral density among men, aged 18-65 years, experiencing
high frequency apheresis over a one year period, we are unable to extrapolate these
findings to women of any age. There remains the possibility that high frequency
apheresis affects women differently than men, particularly during the peri-menopausal
period when changes in serum estrogen have been correlated with large fluctuations in
BMD with supplemental estrogen improving bone-related health outcomes (107, 108).
The scarcity of higher frequency female apheresis donors at the blood center studied
indicate that any exploration of the impact of high frequency apheresis on BMD among
women would require a multi-center design, and, careful consideration of how to
concurrently mitigate the effects of iron deficiency associated with regular platelet
apheresis blood donation (109) that disproportionately impact women (110).
Furthermore, the high prevalence of low BMD among women, especially that increases
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over the life course (111), indicates this would be an ideal group to evaluate the possible
benefit of repeated alterations to PTH through apheresis (53, 112) that resemble those of
synthetic PTH treatments for osteopenia/osteoporosis with demonstrable improvement in
BMD (14).
Before 1988, the US Food and Drug Administration allowed individual volunteer
donors to make 12 apheresis platelet donations per year (9). Two studies presented in an
AABB Advisory Committee comment made in 2006 (113) predate a policy change
increasing the number of donations an individual volunteer donor can make to 24
apheresis platelet donations per rolling 12 month period with no lifetime maximum (114).
In one of these studies (6), 335 donors underwent platelet apheresis at frequent, but
highly varied collection intervals. Initially, platelet count and yield declined to nadir
between the seventh and ninth donation. However, a progressive rise in platelet count
was observed over the course of repeated donations and recovery was achieved at the
tenth donation for many donors despite continued collections. The safety of repeated
collections was illustrated by the fact that at no time a donor exhibited a platelet count
putting them at risk for acute bleeding (8), nor did any develop signs of persistent
thrombocytopenia. A second study (8) is referenced in the Guidance where 105 platelet
apheresis donors of various collection intensities (single, double, and triple product
donors) were assessed for acute thrombocytopenia immediately following collections. It
was reported that post-donation platelet counts never dropped below 100,000/μL. In all
cases of post-donation platelet count falling below 150,000/μL the donor’s platelet count
recovered within the 2 – 4 weeks following donation. Findings from the ALTRUYST
trial extend our understanding of the safety of repeated apheresis platelet collections
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beyond the context of these earlier studies documenting that donors are able to maintain
platelet counts within the normal biological range with repeated donation. The highest
frequency of apheresis blood donation appears safe in terms of platelet recovery and
stresses to mineral homeostasis.
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CONCLUSIONS

Central to the safety and availability of the global blood supply is the community
of volunteer blood donors whose altruism saves the lives of patients in need of
transfusion. Though the collection of blood will inherently confer some risk to blood
donors, it is essential that these risks are calibrated appropriately. In contrast to whole
blood collections, apheresis requires the use of an anticoagulant to prevent extracorporeal
coagulation. Citrate is the industry standard anticoagulant and functions by sequestering
serum ionized calcium. Apheresis blood donors experience exposure to large quantities of
citrate as the mixture of residual blood components and anticoagulant are returned
intravenously. This exposure results in dramatic fluctuations in mineral homeostasis
including changes serum ionized calcium, parathyroid hormone, vitamin D, and markers
of bone metabolism. Cross-sectional studies of bone mineral density among apheresis
blood donors drew conflicting conclusions about the impact of citrate exposure and
skeletal health. ALTRUYST was a prospective, longitudinal, randomized, controlled trial
testing the hypothesis that high frequency apheresis causes declines in bone density.
Forty-one donors completed the study and there was no change in bone mineral density at
any site measured among donors completing a median of 20 apheresis blood donations in
the one year study period. Bone density did not change among members of the control
group who did not undergo apheresis blood donation. Despite significant, repeated
challenges to mineral homeostasis among apheresis blood donors, we conclude that
current collection guidelines adequately protect the skeletal health of adult male, high
frequency apheresis blood donors.
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Appendix 2 – Recruitment Flyer
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Appendix 3 – Recruitment Language

[DATE]

Dear [TITLE] [SURNAME],
As part of your commitment to begin a regular apheresis blood donation program you can help BloodCenter of
Wisconsin advance scientific understanding as part of a study. Eligible donors must be 18-65 years of age and male. If
you choose to participate you will:
•
•
•

fill out a questionnaire
have your bone density evaluated
donate blood for one year

Your participation will help us evaluate if regular apheresis blood donation affects bone density. Your participation will
not have any effect on our ability to use your donated blood products for patient care.
Please contact the BloodCenter research team at 414-937-3851 if you would like more information.
Thank you,
[SIGNATORY]
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Appendix 4 – Questionnaire

Instructions: Please fill in the information or place a checkmark in the bubble next to the appropriate answer for each
question below.
DEMOGRAPHIC INFORMATION
Date of Birth (MM/DD/YYYY): ____/____/__________
Sex:



Age: ________

Male
Female

Ethnicity:
 Hispanic / Latino / Spanish
 Not Hispanic / Latino / Spanish
 I am not sure or do not wish to answer
Race (Check more than one if applicable):
 White / Caucasian
 Black / African American
 Asian
 American Indian / Alaska Native
 Native Hawaiian or other Pacific Islander
 I am not sure or do not wish to answer

STUDY ELIGIBILITY

1.
2.
3.
4.
5.
6.
7.

Are you eligible for whole blood donation?
Do you have a metal prosthesis in your lumbar spine or hip?
Have you experienced a bone fracture in your lumbar spine or hip?
Since you turned 18 years of age, have you experienced a bone
fracture as a result from a fall from standing height or less?
Have you undergone spinal fusion surgery at your lumbar spine?
Have you been diagnosed with cystic fibrosis, emphysema, celiac
disease, and/or Chrohn’s disease?
Are you willing to donate apheresis blood products 20 – 26 times over
the next 12 month period?

Yes

No

























PERSONAL MEDICAL INFORMATION
Have you…
1.
2.
3.
4.
5.

Smoked cigarettes at any time in the past 30 days.
Smoked cigarettes at any time in the past for more than 1 continuous year.
Exercised for more than 20 minutes three times per week in the past 30 days.
Significantly increased or decreased your level of physical activity in the past 6
months.
Significantly changed your diet within the past 12 months.

Yes

No
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FAMILY INFORMATION
Has someone in your family been…
1.
2.
3.
4.
5.
6.

Diagnosed with osteoporosis?
Diagnosed with osteoarthritis?
Diagnosed with rheumatoid arthritis?
Diagnosed with kyphosis or scoliosis?
Treated for a bone fracture - not caused by a trauma (i.e., accident,
fall, etc.)?
A parent was treated for a fractured hip - caused by trauma (i.e.,
accident, fall, etc.)?

Yes

No



















Yes

No







































DIAGNOSIS OF MEDICAL CONDITIONS
Have you been diagnosed by a physician with any of the following?
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.

Osteoporosis
Osteogenesis Imperfecta
Osteopenia
Kyphosis
Scoliosis
Malnutrition
Eating Disorder (Anorexia Nervosa or Bulimia)
Intestinal Disorder
Chronic Liver Disease
Parathyroid Disease
Kidney Disease/Kidney Stones
Thyroid Disease (hyperthyroidism or hypothyroidism)
Diabetes - Type I
Diabetes - Type II
Rheumatoid Arthritis
Hypogonadism
Other Autoimmune Disease
If yes, what kind: _________________________________
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MEDICATION USE

Have you ever taken any of the following medications?

1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.

Steroids or glucocorticoids (prednisone, cortisone, etc.) for more than
three months
Seizure medications (Dilantin, etc.) for chronic management
Thyroid Hormone (Synthroid, Levothroid, Lexoxyl, etc.)
Etidronate (Didronel, Didrocal)
Alendronate (Fosamax)
Risedronate (Actonel)
Tamoxifen (Nolvadex, Istubal, Valodex)
Testosterone (Androderm, Delatestryl)
Nasal Calcitonin (Miacalcin)
Raloxifene (Evista)
Parathyroid Hormone (PTH, Forteo)
Pamidronate (Aredia)
Zoledronic Acid (Zometa, Reclast)
Ibandronate (Boniva)
Clodronate (Bonefos, Ostac)
Sodium Fluoride (Fluotic)
Estrogen
Diabetes medication (insulin, metformin, etc.)
Other Osteoporosis Medication
If yes, what kind: _________________________________

Yes,
Currently
using

Yes, used
in the
past

No
































































Yes

No































DIET & SUPPLEMENT USE
Which of the following do you generally consume?
1.
2.
3.
4.
5.
6.
7.
8.
9.

I generally consume less than 2 servings of dairy per day.
I generally consume less than 2 servings of green, leafy vegetables
per day.
I generally consume less than 2 servings of calcium fortified food
(such as fortified orange juice or fortified soy milk) per day.
I generally consume less than 4 servings of vegetables per day.
I drink more than 2 servings of coffee or soda per day.
I drink more than 8 servings of tea per day.
I drink 3 or more servings of alcohol per day.
I take a vitamin D supplement (includes MVIT and liver oil).
If yes, how many IU per day: _____________________
I take a daily calcium supplement (includes TUMS).
If yes, how many milligrams per day: _____________________
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Appendix 5 – DXA Appointment Letter
[BCW Branding] [Marquette University Branding]
Dear [Title] [Surname]:
Your bone density appointment is scheduled for [TIME] on [DATE]. The Marquette University bone density
scanner is located at 604 N. 16th St in the Department of Physical Therapy. Entrance to this building is on 16th
street and just a few stairs up from the sidewalk. Please go to the second floor.

You will be asked to remove any body piercing or other metal or electronic objects from your body as these
objects interfere with the quality of the images. Please wear comfortable clothing that does not contain metal –
not even a metal eye loop for drawstring shorts.
First, you will lie on your back on a table for approximately 5 – 10 minutes. Then you will lie on your back while
your legs are turned inward for 5 minutes. Finally, you will lie on your back with your legs elevated for 1 minute.
This last scan will be repeated three times.
You will be asked to lie still during your scans. You will change positions for each scan. During the scan, a
mechanical device (the scanner) passes over your body.
We may need to reschedule your appointment if:
•
•
•
•

you have a barium x-ray in the two weeks before your appointment, or;
you have a nuclear medicine scan in the week before your appointment, or;
you have an injection of x-ray dye in the week before your appointment, or;
you are unable to make your appointment for any reason.

Please avoid taking any calcium supplement (including TUMS or multiple vitamins) in the two hours before your
appointment. Please feel free to call 414-881-2130 if you have any questions.
Thank you,
[SIGNATORY]
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Appendix 6 – DXA Notification Letter

[DATE]

Dear [TITLE] [SURNAME],
Thank you for enrolling in the ALTRUYST study. We have reviewed the results from your bone density scans
taken on [DATE OF SCAN]. The purpose of this letter is to inform you that we observed bone density outside
the expected range at one or more of the sites measured. Your individual results are indicated below.
Measurement Site
□ femoral neck

□ total hip

□ lumbar spine (L1-L4)

Z-Score
□ < (-2.0)

□ > (2.0)

DXA Machine
□ Marquette University’s Lunar iDXA
These test results are not cause for immediate concern. Bone density scans performed as part of a research
study are not intended to make clinical diagnoses. Nevertheless, we encourage you to contact your primary
care physician before your next routine clinical examination. Please share this notice with your primary
care physician. You and your physician are welcome to contact me to discuss these results.

Sincerely,

Robert D. Blank, MD, PhD
Chief, Endocrinology, Metabolism, and Clinical Nutrition
Medical College of Wisconsin
(414) 955-6722
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Appendix 7 – Final Appointment Letter
[BCW Branding] [Marquette University Branding]
Dear [Title] [Surname]:
Thank you for participating in the ALTRUYST study!! Your final study visit will include a suite of bone density scans
and completion of a final questionnaire. Your bone density appointment is scheduled for [TIME] on [DATE]. The
Marquette University bone density scanner is located at 604 N. 16th St in the Department of Physical Therapy.
th
Entrance to this building is on 16 street and just a few stairs up from the sidewalk. Please go to the second floor.

You will be asked to remove any body piercing or other metal or electronic objects from your body as these objects
interfere with the quality of the images. Please wear comfortable clothing that does not contain metal – not even a
metal eye loop for drawstring shorts.
We may need to reschedule your appointment if:
• you have a barium x-ray in the two weeks before your appointment, or;
• you have a nuclear medicine scan in the week before your appointment, or;
• you have an injection of x-ray dye in the week before your appointment, or;
• you are unable to make your appointment for any reason.
Please avoid taking any calcium supplement (including TUMS or multiple vitamins) in the two hours before your
appointment. Please feel free to call 414-881-2130 if you have any questions.
You will receive $50 for each of your two completed bone density visits, $100 total, to cover costs associated with
travel. You are also eligible to receive the results of your bone density scans (both from enrollment and final visits)
free of charge.
Study Compliance: On [ENROLLMENT DATE] you were randomly assigned to the [GROUP NAME] group. You were
then asked to [GROUP INSTRUCTIONS]. Our records indicate that you underwent apheresis [# APH] during the one
year period from [ENROLLMENT DATE] through [FINAL DATE]. If you complete your final visit and have otherwise
complied with this study’s protocol, then you will also receive [GROUP RATE]. This compensation is not tied to the
blood donations you made during your participation in the study, but solely for the clinical assessments and
complying with research study guidelines.
We encourage study participants to continue following the progress of this study at the clinicaltrials.gov website:
https://www.clinicaltrials.gov/ct2/show/NCT02655055.
Again, thank you for your valued contribution to this research study. Please contact me with any questions that
you may have.
Sincerely,
[SIGNATORY]
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Appendix 8 – FDA Notice
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Appendix 9 – Syntax for NHANES Extract
> rm(list=ls())
> library(Hmisc)
Loading required package: grid
Loading required package: lattice
Loading required package: survival
Loading required package: Formula
Loading required package: ggplot2
Attaching package: ‘Hmisc’
The following objects are masked from ‘package:base’:
format.pval, round.POSIXt, trunc.POSIXt, units
> ###extract SAS files from NHANES directory
> ###modify location as needed
> spinedata<-sasxport.get("C://NHANES/DATA/DXXSPN_F.XPT")
Processing SAS dataset DXXSPN_F
..
> demodata<-sasxport.get("C://NHANES/DATA/DEMO_F.XPT")
Processing SAS dataset DEMO_F
..
> ###visualize the variables extracted
> names(spinedata)
[1] "seqn" "dxaspnst" "dxxosbcc" "dxxl1bcc" "dxxl2bcc" "dxxl3bcc" "dxxl4bcc" "dxxosbmd" "dxxosbmc"
"dxxosa" "dxxl1bmd"
[12] "dxxl1bmc" "dxxl1a" "dxxl2bmd" "dxxl2bmc" "dxxl2a" "dxxl3bmd" "dxxl3bmc" "dxxl3a" "dxxl4bmd"
"dxxl4bmc" "dxxl4a"
[23] "dxaspnk" "dxaspnd0"
> names(demodata)
[1] "seqn" "sddsrvyr" "ridstatr" "ridexmon" "riagendr" "ridageyr" "ridagemn" "ridageex" "ridreth1"
"dmqmilit" "dmdborn2"
[12] "dmdcitzn" "dmdyrsus" "dmdeduc3" "dmdeduc2" "dmdschol" "dmdmartl" "dmdhhsiz" "dmdfmsiz"
"indhhin2" "indfmin2" "indfmpir"
[23] "ridexprg" "dmdhrgnd" "dmdhrage" "dmdhrbr2" "dmdhredu" "dmdhrmar" "dmdhsedu" "sialang"
"siaproxy" "siaintrp" "fialang"
[34] "fiaproxy" "fiaintrp" "mialang" "miaproxy" "miaintrp" "aialang" "wtint2yr" "wtmec2yr" "sdmvpsu"
"sdmvstra"
> ###merge the two data files
> m<-merge(spinedata,demodata)
> ###visualize the merged variables
> names(m)
[1] "seqn" "dxaspnst" "dxxosbcc" "dxxl1bcc" "dxxl2bcc" "dxxl3bcc" "dxxl4bcc" "dxxosbmd" "dxxosbmc"
"dxxosa" "dxxl1bmd"
[12] "dxxl1bmc" "dxxl1a" "dxxl2bmd" "dxxl2bmc" "dxxl2a" "dxxl3bmd" "dxxl3bmc" "dxxl3a" "dxxl4bmd"
"dxxl4bmc" "dxxl4a"
[23] "dxaspnk" "dxaspnd0" "sddsrvyr" "ridstatr" "ridexmon" "riagendr" "ridageyr" "ridagemn" "ridageex"
"ridreth1" "dmqmilit"
[34] "dmdborn2" "dmdcitzn" "dmdyrsus" "dmdeduc3" "dmdeduc2" "dmdschol" "dmdmartl" "dmdhhsiz"
"dmdfmsiz" "indhhin2" "indfmin2"
[45] "indfmpir" "ridexprg" "dmdhrgnd" "dmdhrage" "dmdhrbr2" "dmdhredu" "dmdhrmar" "dmdhsedu"
"sialang" "siaproxy" "siaintrp"
[56] "fialang" "fiaproxy" "fiaintrp" "mialang" "miaproxy" "miaintrp" "aialang" "wtint2yr" "wtmec2yr"
"sdmvpsu" "sdmvstra"
> ###isolate variables of interest
> ###seqn is the participant sequence number (linking variable)
> ###riagendr=1 for male
> ###ridreth1=3 for non-latino caucasian
> ###ridageyr is age

112

Appendix 10 – Syntax for Power
> ###Appendix: Proposal Simulations 1: Comparison change of
outcome from
> ###before to after for two groups.
> rm(list=ls())
> library(MASS)
> ###simulate test statistic under H0
> ###set population parameters
> ###specify muXbefore, muXafter, muYbefore and muYafter
> ###such that muXafter-muXbefore=muYafter-muYbefore
> muXbefore<-1.054925
> muYbefore<-1.054925
> muXafter<-1.054925
> muYafter<-1.054925
> ###Set parameters for standard error and correlation
> sigmaXbefore<-0.1345117
> sigmaYbefore<-0.1345117
> sigmaXafter<-0.1345117
> sigmaYafter<-0.1345117
> rhoX<-0.95
> rhoY<-0.95
> ###Generate covariance matrix for (Xafter, Xbefore) and (
Yafter, Ybefore)
> VX<-matrix(data=c(sigmaXafter^2,sigmaXafter*sigmaXbefore*
rhoX,sigmaXbefore*sigmaXafter*rhoX,sigmaXbefore^2),ncol=2,n
row=2)
> VY<-matrix(data=c(sigmaYafter^2,sigmaYafter*sigmaYbefore*
rhoY,sigmaYbefore*sigmaYafter*rhoY,sigmaYbefore^2),ncol=2,n
row=2)
> nx<-15
> ny<-45
> m<-10000
> alpha<-0.05
> par(mfrow=c(2,1))
> ###simulate test statistic under H0
> Z0<-rep(NA,m)
> for (i in 1:m){
+
###Sample multivariate normal variables Xbefore and X
after
+
X<-mvrnorm(nx,mu=c(muXafter,muXbefore),Sigma=VX)
+
Y<-mvrnorm(ny,mu=c(muYafter,muYbefore),Sigma=VY)
+
###Begin an experiment and sample data with related v
ariables
+
Xbefore<-X[,2]
+
Ybefore<-Y[,2]
+
Xafter<-X[,1]
+
Yafter<-Y[,1]
+
###Compute change in X and change in Y
+
XD<-Xafter-Xbefore
+
YD<-Yafter-Ybefore
+
###Compute sample standard deviation of XD and YD
+
se<-sqrt(var(XD)/nx+var(YD)/ny)
+
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+
###Compute the statistic as a function of the sample
+
Z0[i]<-(mean(XD)-mean(YD))/se
+ }
> ###show distribution of the test statistic under H0
> hist(Z0,main="Distribution under H0",xlim=c(-10,10))
>
> ###simulate test statistic under Ha
> ###set population parameters
> ###specify muXbefore, muXafter, muYbefore and muYafter
> ###such that muXafter-muXbefore=muYafter-muYbefore
> muXbefore<-1.054925
> muYbefore<-1.054925
> muXafter<-1.054925
> muYafter<-1.02327725
> ###Set parameters for standard error and correlation
> sigmaXbefore<-0.1345117
> sigmaYbefore<-0.1345117
> sigmaXafter<-0.1345117
> sigmaYafter<-0.1345117
> rhoX<-0.95
> rhoY<-0.92
> ####Generate covariance matrix for (Xafter, Xbefore) and
(Yafter, Ybefore)
> VX<-matrix(data=c(sigmaXafter^2,sigmaXafter*sigmaXbefore*
rhoX,sigmaXbefore*sigmaXafter*rhoX,sigmaXbefore^2),ncol=2,n
row=2)
> VY<-matrix(data=c(sigmaYafter^2,sigmaYafter*sigmaYbefore*
rhoY,sigmaYbefore*sigmaYafter*rhoY,sigmaYbefore^2),ncol=2,n
row=2)
> nx<-15
> ny<-45
> m<-10000
> alpha<-0.05
> ###simulate test statistic under Ha
> Z1<-rep(NA,m)
> for (i in 1:m){
+
X<-mvrnorm(nx,mu=c(muXafter,muXbefore),Sigma=VX)
+
Y<-mvrnorm(ny,mu=c(muYafter,muYbefore),Sigma=VY)
+
###Begin an experiment and sample data with related v
ariables
+
Xbefore<-X[,2]
+
Ybefore<-Y[,2]
+
Xafter<-X[,1]
+
Yafter<-Y[,1]
+
###Compute change in X and change in Y
+
XD<-Xafter-Xbefore
+
YD<-Yafter-Ybefore
+
###Compute sample standard deviation of XD and YD
+
se<-sqrt(var(XD)/nx+var(YD)/ny)
+
+
###Compute the statistic as a function of the sample
+
Z1[i]<-(mean(XD)-mean(YD))/se
+ }
> ###show distribution of the test statistic under Ha
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>
>
>
>
>

hist(Z1,main="Distribution under Ha",xlim=c(-10,10))

###obtain critical value
c<-quantile(Z0,probs=1-alpha)
quantile(Z0,probs=1-alpha)
95%
1.720837
>
> ###obtain power
> power<-sum(Z1>c)/m
> power
[1] 0.7362
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Appendix 11 – Syntax for Analysis
##Clear Directory
rm(list=ls())
##Load Libraries
library(xlsx)
library(MASS)
library(ggplot2)
##Identify Working Directory
data<-read.xlsx2("M:/Staff/W Bialkowski/PhD
Marquette/ALTRUYST/Analysis/ALTRUYST Analytic Data
Set.xlsx",
2,
as.data.frame=TRUE,
header=TRUE,
keepFormulas=FALSE,
colClasses=c(rep("numeric",55)))
##Designate Treatment versus Control Groups
msubC<-subset(data,apheresis==0)
msubT<-subset(data,apheresis==1)
##Descriptive table of study subjects at baseline (Table 1
in manuscript)
##Total
summary(data)
sd(data$age,na.rm=TRUE)
sd(data$height,na.rm=TRUE)
sd(data$weight,na.rm=TRUE)
sd(data$BMI,na.rm=TRUE)
sd(data$Na,na.rm=TRUE)
sd(data$K,na.rm=TRUE)
sd(data$Cl,na.rm=TRUE)
sd(data$CO2,na.rm=TRUE)
sd(data$anion,na.rm=TRUE)
sd(data$urea,na.rm=TRUE)
sd(data$creat,na.rm=TRUE)
sd(data$gluc,na.rm=TRUE)
sd(data$alkphos,na.rm=TRUE)
sd(data$AST,na.rm=TRUE)
sd(data$ALT,na.rm=TRUE)
sd(data$Ca,na.rm=TRUE)
sd(data$P,na.rm=TRUE)
sd(data$prot,na.rm=TRUE)
sd(data$alb,na.rm=TRUE)
sd(data$bili,na.rm=TRUE)
sd(data$test,na.rm=TRUE)
sd(data$pre_L1_4,na.rm=TRUE)
sd(data$pre_TH,na.rm=TRUE)
##control
summary(msubC)
sd(msubC$age,na.rm=TRUE)
sd(msubC$height,na.rm=TRUE)
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sd(msubC$weight,na.rm=TRUE)
sd(msubC$BMI,na.rm=TRUE)
sd(msubC$Na,na.rm=TRUE)
sd(msubC$K,na.rm=TRUE)
sd(msubC$Cl,na.rm=TRUE)
sd(msubC$CO2,na.rm=TRUE)
sd(msubC$anion,na.rm=TRUE)
sd(msubC$urea,na.rm=TRUE)
sd(msubC$creat,na.rm=TRUE)
sd(msubC$gluc,na.rm=TRUE)
sd(msubC$alkphos,na.rm=TRUE)
sd(msubC$AST,na.rm=TRUE)
sd(msubC$ALT,na.rm=TRUE)
sd(msubC$Ca,na.rm=TRUE)
sd(msubC$P,na.rm=TRUE)
sd(msubC$prot,na.rm=TRUE)
sd(msubC$alb,na.rm=TRUE)
sd(msubC$bili,na.rm=TRUE)
sd(msubC$test,na.rm=TRUE)
sd(msubC$pre_L1_4,na.rm=TRUE)
sd(msubC$pre_TH,na.rm=TRUE)
##treatment
summary(msubT)
sd(msubT$age,na.rm=TRUE)
sd(msubT$height,na.rm=TRUE)
sd(msubT$weight,na.rm=TRUE)
sd(msubT$BMI,na.rm=TRUE)
sd(msubT$Na,na.rm=TRUE)
sd(msubT$K,na.rm=TRUE)
sd(msubT$Cl,na.rm=TRUE)
sd(msubT$CO2,na.rm=TRUE)
sd(msubT$anion,na.rm=TRUE)
sd(msubT$urea,na.rm=TRUE)
sd(msubT$creat,na.rm=TRUE)
sd(msubT$gluc,na.rm=TRUE)
sd(msubT$alkphos,na.rm=TRUE)
sd(msubT$AST,na.rm=TRUE)
sd(msubT$ALT,na.rm=TRUE)
sd(msubT$Ca,na.rm=TRUE)
sd(msubT$P,na.rm=TRUE)
sd(msubT$prot,na.rm=TRUE)
sd(msubT$alb,na.rm=TRUE)
sd(msubT$bili,na.rm=TRUE)
sd(msubT$test,na.rm=TRUE)
sd(msubT$pre_L1_4,na.rm=TRUE)
sd(msubT$pre_TH,na.rm=TRUE)
##view distributions
par(mfrow=c(2,2))
hist.default(data$age, xlab="Age (years)",
main="Distribution of Age")
hist.default(data$height, xlab="Height (inches)",
main="Distribution of Height")
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hist.default(data$weight, xlab="Weight (pounds)",
main="Distribution of Weight")
hist.default(data$BMI, xlab="BMI (%)", main="Distribution
of BMI")
par(mfrow=c(2,2))
hist.default(data$Na, xlab="Serum Sodium (mmol/L)",
main="Distribution of Serum Sodium")
hist.default(data$K, xlab="Serum Potassium (mmol/L)",
main="Distribution of Serum Potassium")
hist.default(data$Cl, xlab="Serum Chloride (mmol/L))",
main="Distribution of Serum Chloride")
hist.default(data$CO2, xlab="Serum CO2 (mmol/L)",
main="Distribution of Serum CO2")
par(mfrow=c(2,2))
hist.default(data$anion, xlab="Anion Gap (mmol/L)",
main="Distribution of Anion Gap")
hist.default(data$urea, xlab="Urea (mg/dL)",
main="Distribution of Urea")
hist.default(data$creat, xlab="Serum Creatinine (mg/dL)",
main="Distribution of Serum Creatinine")
hist.default(data$gluc, xlab="Serum Glucose (mg/dL)",
main="Distribution of Serum Glucose")
par(mfrow=c(2,2))
hist.default(data$alkphos, xlab="Alkaline Phosphatase
(U/L)", main="Distribution of Alkaline Phosphatase")
hist.default(data$ALT, xlab="ALT (U/L)", main="Distribution
of ALT")
hist.default(data$AST, xlab="AST (U/L)", main="Distribution
of AST")
hist.default(data$Ca, xlab="Serum Calcium (mg/dL)",
main="Distribution of Serum Calcium")
par(mfrow=c(2,2))
hist.default(data$P, xlab="Serum Phosphorous (mg/dL)",
main="Distribution of Serum Phosphorous")
hist.default(data$prot, xlab="Serum Protein (g/dL)",
main="Distribution of Serum Protein")
hist.default(data$alb, xlab="Serum Albumin (g/dL)",
main="Distribution of Serum Albumin")
hist.default(data$bili, xlab="Serum Bilirubin (mg/dL)",
main="Distribution of Serum Bilirubin")
par(mfrow=c(2,2))
hist.default(data$test, xlab="Male Adult Testosterone
(ng/dL)", main="Distribution of Testosterone")
hist.default(data$pre_L1_4, xlab="Pre Lumbar Spine
(g/cm^2)", main="Distribution of Pre Lumbar Spine")
hist.default(data$pre_TH, xlab="Pre Total Hip (g/cm^2)",
main="Distribution of Pre Total Hip")
##side-by-side transformations
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par(mfrow=c(3,2))
hist.default(data$anion, xlab="Anion Gap before
transformation", main="Distribution of Anion Gap")
hist.default(log(data$anion), xlab="Anion Gap after
transformation", main="Distribution of Anion Gap")
hist.default(data$alkphos, xlab="Alkaline Phosphatase
before transformation", main="Distribution of Alkaline
Phosphatase")
hist.default(log(data$alkphos), xlab="Alkaline Phosphatase
after transformation", main="Distribution of Alkaline
Phosphatase")
hist.default(data$bili, xlab="Bilirubin before
transformation", main="Distribution of Bilirubin")
hist.default(log(data$bili), xlab="Bilirubin after
transformation", main="Distribution of Bilirubin")
##log transform anion, alkphos, and bili
loganion<-log10(data$anion)
logalkphos<-log10(data$alkphos)
logbili<-log10(data$bili)
##Test for differences
##Fishers Exact for Categorical; T-Test for Continuous
fisher.test(msubC$race,msubT$race)
fisher.test(msubC$ethn,msubT$ethn)
t.test(msubC$age,msubT$age)
t.test(msubC$height,msubT$height)
t.test(msubC$weight,msubT$weight)
t.test(msubC$BMI,msubT$BMI)
t.test(msubC$Na,msubT$Na)
t.test(msubC$K,msubT$K)
t.test(msubC$Cl,msubT$Cl)
t.test(msubC$CO2,msubT$CO2)
t.test(msubC$loganion,msubT$loganion)
t.test(msubC$urea,msubT$urea)
t.test(msubC$creat,msubT$creat)
t.test(msubC$gluc,msubT$gluc)
t.test(msubC$logalkphos,msubT$logalkphos)
t.test(msubC$AST,msubT$AST)
t.test(msubC$ALT,msubT$ALT)
t.test(msubC$Ca,msubT$Ca)
t.test(msubC$P,msubT$P)
t.test(msubC$prot,msubT$prot)
t.test(msubC$alb,msubT$alb)
t.test(msubC$logbili,msubT$logbili)
t.test(msubC$test,msubT$test)
t.test(msubC$pre_L1_4,msubT$pre_L1_4)
t.test(msubC$pre_TH,msubT$pre_TH)
##visualize distributions of BMD at enrollment
par(mfrow=c(3,2))
hist(data$pre_L1_4,xlim = c(0.9,1.5),ylim=c(0,12))
hist(data$pre_TH,xlim = c(0.8,1.5),ylim=c(0,12))
hist(msubC$pre_L1_4,xlim = c(0.9,1.5),ylim=c(0,6))
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hist(msubC$pre_TH,xlim = c(0.8,1.5),ylim=c(0,6))
hist(msubT$pre_L1_4,xlim = c(0.9,1.5),ylim=c(0,12))
hist(msubT$pre_TH,xlim = c(0.8,1.5),ylim=c(0,12))
##Visualize BMD at enrollment for Both Groups
##there's a number of ways I'm considering illustrating
these
##this is an example
ggplot(data, aes(x=test)) +
geom_density(aes(stat="density"),
binwidth=0.5,
colour="black",
fill="white") +
geom_density(alpha=.2, fill="#FF6666")
par(mfrow=c(2,1))
ggplot(data, aes(x=SubjectID,
y=pre_TH))+
geom_point(size=1.5, shape=21, fill="white")+
labs(title="Baseline TH BMD, Both Groups")
ggplot(data, aes(x=SubjectID,
y=pre_L1_4))
+ ggtitle("Baseline L Spine BMD, Both Groups")
##Visualize
##Visualize
##Visualize
##Visualize
##Visualize

BMD at enrollment for Controls
BMD at enrollment for Treatment
Final BMD for Both Groups
Final BMD for Controls
Final BMD for Treatment

##compute mean at enrollment
mean(data$pre_TH)
sd(data$pre_TH)
mean(data$pre_L1_4)
sd(data$pre_L1_4)
mean(msubC$pre_TH)
sd(msubC$pre_TH)
mean(msubT$pre_TH)
sd(msubT$pre_TH)
mean(msubC$pre_L1_4)
sd(msubC$pre_L1_4)
mean(msubT$pre_L1_4)
sd(msubT$pre_L1_4)
mean(msubC$pre_TBS,na.rm=TRUE)
sd(msubC$pre_TBS,na.rm=TRUE)
mean(msubT$pre_TBS,na.rm=TRUE)
sd(msubT$pre_TBS,na.rm=TRUE)
mean(msubC$pre_neck)
sd(msubC$pre_neck)
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mean(msubT$pre_neck)
sd(msubT$pre_neck)
##compute mean at follow-up
mean(msubC$post_TH)
sd(msubC$post_TH)
mean(msubT$post_TH)
sd(msubT$post_TH)
mean(msubC$post_L1_4)
sd(msubC$post_L1_4)
mean(msubT$post_L1_4)
sd(msubT$post_L1_4)
mean(msubC$post_TBS,na.rm=TRUE)
sd(msubC$post_TBS,na.rm=TRUE)
mean(msubT$post_TBS,na.rm=TRUE)
sd(msubT$post_TBS,na.rm=TRUE)
mean(msubC$post_neck)
sd(msubC$post_neck)
mean(msubT$post_neck)
sd(msubT$post_neck)
##create derived 'change in BMD' variables
deltaTH<-(data$post_TH-data$pre_TH)
deltaL1_4<-(data$post_L1_4-data$pre_L1_4)
deltaTHC<-(msubC$post_TH-msubC$pre_TH)
deltaL1_4C<-(msubC$post_L1_4-msubC$pre_L1_4)
deltaTBSC<-(msubC$post_TBS-msubC$pre_TBS)
deltaneckC<-(msubC$post_neck-msubC$pre_neck)
deltaTHT<-(msubT$post_TH-msubT$pre_TH)
deltaL1_4T<-(msubT$post_L1_4-msubT$pre_L1_4)
deltaTBST<-(msubT$post_TBS-msubT$pre_TBS)
deltaneckT<-(msubT$post_neck-msubT$pre_neck)
##Compute mean change
mean(deltaTHC)
sd(deltaTHC)
mean(deltaTHT)
sd (deltaTHT)
mean(deltaL1_4C)
sd(deltaL1_4C)
mean(deltaL1_4T)
sd(deltaL1_4T)
mean(deltaTBSC,na.rm=TRUE)
sd(deltaTBSC,na.rm=TRUE)
mean(deltaTBST)
sd(deltaTBST)
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mean(deltaneckC)
sd(deltaneckC)
mean(deltaneckT)
sd(deltaneckT)
##95% CIs and p values
t.test(deltaTHC)
t.test(deltaL1_4C)
t.test(deltaTHT)
t.test(deltaL1_4T)
t.test(deltaTBSC,na.rm=TRUE)
t.test(deltaTBST)
t.test(deltaneckC)
t.test(deltaneckT)
##hists
par(mfrow=c(2,2))
hist(deltaL1_4C,xlim=c(-0.1,0.1),ylim=c(0,15),main="Delta L
Spine Control",nclass=5)
hist(deltaL1_4T,xlim=c(-0.1,0.1),ylim=c(0,15),main="Delta L
Spine Apheresis",nclass=10)
hist(deltaTHC,xlim=c(-0.1,0.1),ylim=c(0,15),main="Delta TH
Controls",nclass=5)
hist(deltaTHT,xlim=c(-0.1,0.1),ylim=c(0,15),main="Delta TH
Apheresis",nclass=10)
##compare mean change to LSC in treated
##LSC at lumbar spine is 0.00743
if((mean(deltaL1_4T))>0.00743)
print("mean change among treated subjects exceeds LSC for
lumbar spine in the positive direction")
if((mean(deltaL1_4T))<(-0.00743))
print("mean change among treated subjects exceeds LSC for
lumbar spine in the negative direction")
##LSC at TH is 0.00671
if((mean(deltaTHT))>0.00671)
print("mean change for treated subjects exceeds LSC for
total hip in the positive direction")
if((mean(deltaTHT))<(-0.00671))
print("mean change for treated subjects exceeds LSC for
total hip in the negative direction")
##compare mean change to LSC in controls
##LSC at lumbar spine is 0.00743
if((mean(deltaL1_4C))>0.00743)
print("mean change among control subjects exceeds LSC for
lumbar spine in the positive direction")
if((mean(deltaL1_4C))<(-0.00743))
print("mean change among control subjects exceeds LSC for
lumbar spine in the negative direction")
##LSC at TH is 0.00671
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if((mean(deltaTHC))>0.00671)
print("mean change for control subjects exceeds LSC for
total hip in the positive direction")
if((mean(deltaTHC))<(-0.00671))
print("mean change for control subjects exceeds LSC for
total hip in the negative direction")
##plain t test for differences
t.test(deltaL1_4C,deltaL1_4T)
t.test(deltaTHC,deltaTHT)
##Visualize change in BMD for both groups
par(mfrow=c(2,2))
plot(deltaL1_4C, ylim=c(-0.17,0.17))
plot(deltaL1_4T, ylim=c(-0.17,0.17))
plot(deltaTHC, ylim=c(-0.17,0.17))
plot(deltaTHT, ylim=c(-0.17,0.17))
##Boxplots change in BMD
par(mfrow=c(2,2))
boxplot(deltaL1_4C, ylim=c(-0.1,0.1),main="L spine
control")
boxplot(deltaL1_4T, ylim=c(-0.1,0.1),main="L spine
treated")
boxplot(deltaTHC, ylim=c(-0.05,0.05),main="hip control")
boxplot(deltaTHT, ylim=c(-0.05,0.05),main="hip treated")
##create Figure 3 for main paper - box plots
ggplot(data, aes(x=factor(apheresis), y=deltaL1_4))+
ylim(-0.06,0.06)+
geom_boxplot()+
theme_bw()+
stat_summary(fun.y="mean", geom="point", shape=23,
size=3, fill="black")+
annotate("rect",xmin=0.5,xmax=2.5,alpha=0.1,ymin=0.00743,ymax=0.00743,fill="blue")+
theme(panel.border = element_blank(),
panel.grid.major = element_blank(),
panel.grid.major.y = element_line(linetype =
"dashed", colour = "black"),
panel.grid.minor = element_blank(),
panel.background = element_blank(),
axis.line = element_line(colour = "white"))
ggplot(data, aes(x=factor(apheresis), y=deltaTH))+
ylim(-0.06,0.06)+
geom_boxplot()+
theme_bw()+
stat_summary(fun.y="mean", geom="point", shape=23,
size=3, fill="black")+
annotate("rect",xmin=0.5,xmax=2.5,alpha=0.1,ymin=0.00743,ymax=0.00743,fill="blue")+
theme(panel.border = element_blank(),
panel.grid.major = element_blank(),
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panel.grid.major.y = element_line(linetype =
"dashed", colour = "black"),
panel.grid.minor = element_blank(),
panel.background = element_blank(),
axis.line = element_line(colour = "white"))
##Define Number of Subjects Analyzed in Each Group
nC<-15
nT<-26
##BEGIN: Unadjusted Analysis
##Compute and Show Standard Errors
vardeltaTHC<-var(deltaTHC)
vardeltaTHC
vardeltaL1_4C<-var(deltaL1_4C)
vardeltaL1_4C
vardeltaTHT<-var(deltaTHT)
vardeltaTHT
vardeltaL1_4T<-var(deltaL1_4T)
vardeltaL1_4T
##Test for Differences in Baseline BMD by treatment arm
TTH<-(mean(deltaTHC)mean(deltaTHT))/sqrt((vardeltaTHC/nC)+(vardeltaTHT/nT))
TTH
TL1_4<-(mean(deltaL1_4C)mean(deltaL1_4T))/sqrt((vardeltaL1_4C/nC)+(vardeltaL1_4T/nT
))
TL1_4
##compute degrees of freedom
vTH<-((vardeltaTHC/nC)+(vardeltaTHT/nT))/
((((vardeltaTHC/nC)^2)/(nC-1))+(((vardeltaTHT/nT)^2)/(nT1)))
VTH
vL1_4<-((vardeltaL1_4C/nC)+(vardeltaL1_4T/nT))/
((((vardeltaL1_4C/nC)^2)/(nC1))+(((vardeltaL1_4T/nT)^2)/(nT-1)))
vL1_4
##derive critical value
qtTH<-qt(c(0.95),df=vTH)
qtTH
qtL1_4<-qt(c(0.95),df=vL1_4)
qtL1_4
##output messaging
if((TTH-qtTH)>0)
print("reject the null hypothesis for total hip")
if((TTH-qtTH)<=0)
print("you are not able to reject the null hypothesis for
total hip")
if((TL1_4-qtL1_4)>0)
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print("reject the null hypothesis for lumbar spine")
if((TL1_4-qtL1_4)<=0)
print("you are not able to reject the null hypothesis for
lumbar spine")
##test for difference in proportions
LspineI<-matrix(c(8,7,13,13),byrow=TRUE, 2, 2)
LspineI
chisq.test(LspineI, correct = FALSE)
LspineD<-matrix(c(5,10,8,18),byrow=TRUE, 2, 2)
LspineD
chisq.test(LspineD, correct = FALSE)
THI<-matrix(c(6,9,6,20),byrow=TRUE, 2, 2)
THI
chisq.test(THI, correct = FALSE)
THD<-matrix(c(3,12,11,15),byrow=TRUE, 2, 2)
THD
chisq.test(THD, correct = FALSE)
##END: Unadjusted Analysis
##BEGIN Adjusted Analysis Using Multivariable Linear
Regression
##visualize distributions of participant demographic and
behavioral characteristics
##can also do str function for each predictor to examine
potential extreme values
##can also do stem and leaf plots
##can do scatterplots to evaluate need for transformations
##can also test for correlations using Pearsons/Spearmans
##can test linearity using Shapiro-Wilk's
##can evaluate leverage values
##can do QQ plots
##can do Jackknife Residuals
##can do Cook's Distance
##can evaluate collinearity with rcorr function
##can do Variance Inflation Factors (VIF>10 interrogation)
##can evaluate multicollinearity with Tolerance Values,
Eigenvalues, Condition Indices/Numbers
par(mfrow=c(3,2))
hist(data$age)
hist(data$risks)
hist(data$family)
hist(data$conditions)
hist(data$medications)
hist(data$diet)
##negative change in L spine
fitnL1_4<-lm(data$bigndeltaL1_4~
(data$apheresis)+
(data$age)+
(as.factor(data$risks))+
(as.factor(data$family))+
(as.factor(data$conditions))+
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(as.factor(data$medications))+
(as.factor(data$diet))+
(data$BMI)+
(data$pre_L1_4)+
(data$Na)+
(data$K)+
(data$Cl)+
(data$CO2)+
(data$anion)+
(data$urea)+
(data$creat)+
(data$gluc)+
(data$alkphos)+
(data$AST)+
(data$ALT)+
(data$Ca)+
(data$P)+
(data$prot)+
(data$alb)+
(data$bili)+
(data$test))
summary(fitnL1_4)
anova(fitnL1_4)
##stepwise backwards elimination for negative change in L
spine
stepnL1_4<-stepAIC(fitnL1_4,direction="backward")
stepnL1_4$anova
##positive change in L spine
fitpL1_4<-lm(data$bigpdeltaL1_4~
(data$apheresis)+
(data$age)+
(as.factor(data$risks))+
(as.factor(data$family))+
(as.factor(data$conditions))+
(as.factor(data$medications))+
(as.factor(data$diet))+
(data$BMI)+
(data$pre_L1_4)+
(data$Na)+
(data$K)+
(data$Cl)+
(data$CO2)+
(data$anion)+
(data$urea)+
(data$creat)+
(data$gluc)+
(data$alkphos)+
(data$AST)+
(data$ALT)+
(data$Ca)+
(data$P)+
(data$prot)+
(data$alb)+
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(data$bili)+
(data$test))
summary(fitpL1_4)
anova(fitpL1_4)
##stepwise backwards elimination for positive change in L
spine
steppL1_4<-stepAIC(fitpL1_4,direction="backward")
steppL1_4$anova
##negative change in total hip
fitnTH<-lm(data$bigndeltaTH~
(data$apheresis)+
(data$age)+
(as.factor(data$risks))+
(as.factor(data$family))+
(as.factor(data$conditions))+
(as.factor(data$medications))+
(as.factor(data$diet))+
(data$BMI)+
(data$pre_TH)+
(data$Na)+
(data$K)+
(data$Cl)+
(data$CO2)+
(data$anion)+
(data$urea)+
(data$creat)+
(data$gluc)+
(data$alkphos)+
(data$AST)+
(data$ALT)+
(data$Ca)+
(data$P)+
(data$prot)+
(data$alb)+
(data$bili)+
(data$test))
summary(fitnTH)
anova(fitnTH)
##stepwise backwards elimination for negative change in L
spine
stepnTH<-stepAIC(fitnTH,direction="backward")
stepnTH$anova
##positive change in TH
fitpTH<-lm(data$bigpdeltaTH~
(data$apheresis)+
(data$age)+
(as.factor(data$risks))+
(as.factor(data$family))+
(as.factor(data$conditions))+
(as.factor(data$medications))+
(as.factor(data$diet))+
(data$BMI)+
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(data$pre_TH)+
(data$Na)+
(data$K)+
(data$Cl)+
(data$CO2)+
(data$anion)+
(data$urea)+
(data$creat)+
(data$gluc)+
(data$alkphos)+
(data$AST)+
(data$ALT)+
(data$Ca)+
(data$P)+
(data$prot)+
(data$alb)+
(data$bili)+
(data$test))
summary(fitpTH)
anova(fitpTH)
##stepwise backwards elimination for positive change in L
spine
steppTH<-stepAIC(fitpTH,direction="backward")
steppTH$anova

##Everything prior was the intention to treat analysis
##we can now perform the same analyses limited to protocol
compliers
##i.e. ITT=1 in the data set
##see programming for "ALRUYST Coding compliers" and .xlsx
file ...compliers.xlsx
wb<-c(6,4,5,4,5,5,4,2,1,1,1,0,0,0,0)
median(wb)
mean(wb)
sd(wb)
##Clear Directory
rm(list=ls())
##Load Libraries
library(xlsx)
library(MASS)
library(ggplot2)
##Identify Working Directory
data<-read.xlsx2("M:/Staff/W Bialkowski/PhD
Marquette/ALTRUYST/Analysis/ALTRUYST Analytic Data Set
compliers.xlsx",
2,
as.data.frame=TRUE,
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header=TRUE,
keepFormulas=FALSE,
colClasses=c(rep("numeric",68)))
##Designate Treatment versus Control Groups
msubC<-subset(data,apheresis==0)
msubT<-subset(data,apheresis==1)
##Descriptive table of study subjects at baseline (Table 1
in manuscript)
##Total
summary(data)
sd(data$age,na.rm=TRUE)
sd(data$height,na.rm=TRUE)
sd(data$weight,na.rm=TRUE)
sd(data$BMI,na.rm=TRUE)
sd(data$Na,na.rm=TRUE)
sd(data$K,na.rm=TRUE)
sd(data$Cl,na.rm=TRUE)
sd(data$CO2,na.rm=TRUE)
sd(data$anion,na.rm=TRUE)
sd(data$urea,na.rm=TRUE)
sd(data$creat,na.rm=TRUE)
sd(data$gluc,na.rm=TRUE)
sd(data$alkphos,na.rm=TRUE)
sd(data$ALT,na.rm=TRUE)
sd(data$AST,na.rm=TRUE)
sd(data$Ca,na.rm=TRUE)
sd(data$P,na.rm=TRUE)
sd(data$prot,na.rm=TRUE)
sd(data$alb,na.rm=TRUE)
sd(data$bili,na.rm=TRUE)
sd(data$test,na.rm=TRUE)
sd(data$pre_L1_4,na.rm=TRUE)
sd(data$pre_TH,na.rm=TRUE)
##control
summary(msubC)
sd(msubC$age,na.rm=TRUE)
sd(msubC$height,na.rm=TRUE)
sd(msubC$weight,na.rm=TRUE)
sd(msubC$BMI,na.rm=TRUE)
sd(msubC$Na,na.rm=TRUE)
sd(msubC$K,na.rm=TRUE)
sd(msubC$Cl,na.rm=TRUE)
sd(msubC$CO2,na.rm=TRUE)
sd(msubC$anion,na.rm=TRUE)
sd(msubC$urea,na.rm=TRUE)
sd(msubC$creat,na.rm=TRUE)
sd(msubC$gluc,na.rm=TRUE)
sd(msubC$alkphos,na.rm=TRUE)
sd(msubC$ALT,na.rm=TRUE)
sd(msubC$AST,na.rm=TRUE)
sd(msubC$Ca,na.rm=TRUE)
sd(msubC$P,na.rm=TRUE)
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sd(msubC$prot,na.rm=TRUE)
sd(msubC$alb,na.rm=TRUE)
sd(msubC$bili,na.rm=TRUE)
sd(msubC$test,na.rm=TRUE)
sd(msubC$pre_L1_4,na.rm=TRUE)
sd(msubC$pre_TH,na.rm=TRUE)
##treatment
summary(msubT)
sd(msubT$age,na.rm=TRUE)
sd(msubT$height,na.rm=TRUE)
sd(msubT$weight,na.rm=TRUE)
sd(msubT$BMI,na.rm=TRUE)
sd(msubT$Na,na.rm=TRUE)
sd(msubT$K,na.rm=TRUE)
sd(msubT$Cl,na.rm=TRUE)
sd(msubT$CO2,na.rm=TRUE)
sd(msubT$anion,na.rm=TRUE)
sd(msubT$urea,na.rm=TRUE)
sd(msubT$creat,na.rm=TRUE)
sd(msubT$gluc,na.rm=TRUE)
sd(msubT$alkphos,na.rm=TRUE)
sd(msubT$ALT,na.rm=TRUE)
sd(msubT$AST,na.rm=TRUE)
sd(msubT$Ca,na.rm=TRUE)
sd(msubT$P,na.rm=TRUE)
sd(msubT$prot,na.rm=TRUE)
sd(msubT$alb,na.rm=TRUE)
sd(msubT$bili,na.rm=TRUE)
sd(msubT$test,na.rm=TRUE)
sd(msubT$pre_L1_4,na.rm=TRUE)
sd(msubT$pre_TH,na.rm=TRUE)
##Test for differences
##Fishers Exact for Categorical; T-Test for Continuous
fisher.test(msubC$race,msubT$race)
fisher.test(msubC$ethn,msubT$ethn)
t.test(msubC$age,msubT$age)
t.test(msubC$height,msubT$height)
t.test(msubC$weight,msubT$weight)
t.test(msubC$BMI,msubT$BMI)
t.test(msubC$prev_WB,msubT$prev_WB)
t.test(msubC$prev_Aph,msubT$prev_Aph)
t.test(msubC$Na,msubT$Na)
t.test(msubC$K,msubT$K)
t.test(msubC$Cl,msubT$Cl)
t.test(msubC$CO2,msubT$CO2)
t.test(msubC$anion,msubT$anion)
t.test(msubC$urea,msubT$urea)
t.test(msubC$creat,msubT$creat)
t.test(msubC$gluc,msubT$gluc)
t.test(msubC$alkphos,msubT$alkphos)
t.test(msubC$AST,msubT$AST)
t.test(msubC$ALT,msubT$ALT)
t.test(msubC$Ca,msubT$Ca)
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t.test(msubC$P,msubT$P)
t.test(msubC$prot,msubT$prot)
t.test(msubC$alb,msubT$alb)
t.test(msubC$bili,msubT$bili)
t.test(msubC$test,msubT$test)
t.test(msubC$pre_L1_4,msubT$pre_L1_4)
t.test(msubC$pre_TH,msubT$pre_TH)
##visualize distributions of BMD at enrollment
par(mfrow=c(3,2))
hist(data$pre_L1_4)
hist(data$pre_TH)
hist(msubC$pre_L1_4)
hist(msubC$pre_TH)
hist(msubT$pre_L1_4)
hist(msubT$pre_TH)
##Visualize BMD at enrollment for Both Groups
##there's a number of ways I'm considering illustrating
these
##this is an example
ggplot(data, aes(x=test)) +
geom_density(aes(stat="density"),
binwidth=0.5,
colour="black",
fill="white") +
geom_density(alpha=.2, fill="#FF6666")
par(mfrow=c(2,1))
ggplot(data, aes(x=SubjectID,
y=pre_TH))+
geom_point(size=1.5, shape=21, fill="white")+
labs(title="Baseline TH BMD, Both Groups")
ggplot(data, aes(x=SubjectID,
y=pre_L1_4))
+ ggtitle("Baseline L Spine BMD, Both Groups")
##Visualize
##Visualize
##Visualize
##Visualize
##Visualize

BMD at enrollment for Controls
BMD at enrollment for Treatment
Final BMD for Both Groups
Final BMD for Controls
Final BMD for Treatment

##create derived 'change in BMD' variables
deltaTH<-(data$post_TH-data$pre_TH)
deltaL1_4<-(data$post_L1_4-data$pre_L1_4)
deltaTHC<-(msubC$post_TH-msubC$pre_TH)
deltaTHC
deltaL1_4C<-(msubC$post_L1_4-msubC$pre_L1_4)
deltaL1_4C
deltaTHT<-(msubT$post_TH-msubT$pre_TH)
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deltaTHT
deltaL1_4T<-(msubT$post_L1_4-msubT$pre_L1_4)
deltaL1_4T
##compute mean at enrollment
mean(msubC$pre_TH)
sd(msubC$pre_TH)
mean(msubT$pre_TH)
sd(msubT$pre_TH)
mean(msubC$pre_L1_4)
sd(msubC$pre_L1_4)
mean(msubT$pre_L1_4)
sd(msubT$pre_L1_4)
##compute mean at follow-up
mean(msubC$post_TH)
sd(msubC$post_TH)
mean(msubT$post_TH)
sd(msubT$post_TH)
mean(msubC$post_L1_4)
sd(msubC$post_L1_4)
mean(msubT$post_L1_4)
sd(msubT$post_L1_4)
##Compute mean change
mean(deltaTHC)
sd(deltaTHC)
mean(deltaTHT)
sd (deltaTHT)
mean(deltaL1_4C)
sd(deltaL1_4C)
mean(deltaL1_4T)
sd(deltaL1_4T)
##hists
par(mfrow=c(2,2))
hist(deltaL1_4C,xlim=c(-0.1,0.1),ylim=c(0,15),main="Delta L
Spine Control",nclass=5)
hist(deltaL1_4T,xlim=c(-0.1,0.1),ylim=c(0,15),main="Delta L
Spine Apheresis",nclass=10)
hist(deltaTHC,xlim=c(-0.1,0.1),ylim=c(0,15),main="Delta TH
Controls",nclass=5)
hist(deltaTHT,xlim=c(-0.1,0.1),ylim=c(0,15),main="Delta TH
Apheresis",nclass=10)
##plain t test for differences
t.test(deltaL1_4C,deltaL1_4T)
t.test(deltaTHC,deltaTHT)
##Visualize change in BMD for both groups
par(mfrow=c(2,2))
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plot(deltaL1_4C, ylim=c(-0.17,0.17))
plot(deltaL1_4T, ylim=c(-0.17,0.17))
plot(deltaTHC, ylim=c(-0.17,0.17))
plot(deltaTHT, ylim=c(-0.17,0.17))
##Boxplots change in BMD
par(mfrow=c(2,2))
boxplot(deltaL1_4C, ylim=c(-0.1,0.1),main="L spine
control")
boxplot(deltaL1_4T, ylim=c(-0.1,0.1),main="L spine
treated")
boxplot(deltaTHC, ylim=c(-0.05,0.05),main="hip control")
boxplot(deltaTHT, ylim=c(-0.05,0.05),main="hip treated")
##create Figure 3 for main paper - box plots
ggplot(data, aes(x=factor(apheresis), y=deltaL1_4))+
ylim(-0.06,0.06)+
geom_boxplot()+
theme_bw()+
stat_summary(fun.y="mean", geom="point", shape=23,
size=3, fill="black")+
annotate("rect",xmin=0.5,xmax=2.5,alpha=0.1,ymin=0.00743,ymax=0.00743,fill="blue")+
theme(panel.border = element_blank(),
panel.grid.major = element_blank(),
panel.grid.major.y = element_line(linetype =
"dashed", colour = "black"),
panel.grid.minor = element_blank(),
panel.background = element_blank(),
axis.line = element_line(colour = "white"))
ggplot(data, aes(x=factor(apheresis), y=deltaTH))+
ylim(-0.06,0.06)+
geom_boxplot()+
theme_bw()+
stat_summary(fun.y="mean", geom="point", shape=23,
size=3, fill="black")+
annotate("rect",xmin=0.5,xmax=2.5,alpha=0.1,ymin=0.00743,ymax=0.00743,fill="blue")+
theme(panel.border = element_blank(),
panel.grid.major = element_blank(),
panel.grid.major.y = element_line(linetype =
"dashed", colour = "black"),
panel.grid.minor = element_blank(),
panel.background = element_blank(),
axis.line = element_line(colour = "white"))
##compare mean change to LSC in treated
##LSC at lumbar spine is 0.00743
if((mean(deltaL1_4T))>0.00743)
print("mean change among treated subjects exceeds LSC for
lumbar spine in the positive direction")
if((mean(deltaL1_4T))<(-0.00743))
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print("mean change among treated subjects exceeds LSC for
lumbar spine in the negative direction")
##LSC at TH is 0.00671
if((mean(deltaTHT))>0.00671)
print("mean change for treated subjects exceeds LSC for
total hip in the positive direction")
if((mean(deltaTHT))<(-0.00671))
print("mean change for treated subjects exceeds LSC for
total hip in the negative direction")
##compare mean change to LSC in controls
##LSC at lumbar spine is 0.00743
if((mean(deltaL1_4C))>0.00743)
print("mean change among control subjects exceeds LSC for
lumbar spine in the positive direction")
if((mean(deltaL1_4C))<(-0.00743))
print("mean change among control subjects exceeds LSC for
lumbar spine in the negative direction")
##LSC at TH is 0.00671
if((mean(deltaTHC))>0.00671)
print("mean change for control subjects exceeds LSC for
total hip in the positive direction")
if((mean(deltaTHC))<(-0.00671))
print("mean change for control subjects exceeds LSC for
total hip in the negative direction")
##Define Number of Subjects Analyzed in Each Group
nC<-15
nT<-21
##BEGIN: Unadjusted Analysis
##Compute and Show Standard Errors
vardeltaTHC<-var(deltaTHC)
vardeltaTHC
vardeltaL1_4C<-var(deltaL1_4C)
vardeltaL1_4C
vardeltaTHT<-var(deltaTHT)
vardeltaTHT
vardeltaL1_4T<-var(deltaL1_4T)
vardeltaL1_4T
##Test for Differences in Baseline BMD by treatment arm
TTH<-(mean(deltaTHC)mean(deltaTHT))/sqrt((vardeltaTHC/nC)+(vardeltaTHT/nT))
TTH
TL1_4<-(mean(deltaL1_4C)mean(deltaL1_4T))/sqrt((vardeltaL1_4C/nC)+(vardeltaL1_4T/nT
))
TL1_4
##compute degrees of freedom
vTH<-((vardeltaTHC/nC)+(vardeltaTHT/nT))/
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((((vardeltaTHC/nC)^2)/(nC-1))+(((vardeltaTHT/nT)^2)/(nT1)))
VTH
vL1_4<-((vardeltaL1_4C/nC)+(vardeltaL1_4T/nT))/
((((vardeltaL1_4C/nC)^2)/(nC1))+(((vardeltaL1_4T/nT)^2)/(nT-1)))
vL1_4
##derive critical value
qtTH<-qt(c(0.95),df=vTH)
qtTH
qtL1_4<-qt(c(0.95),df=vL1_4)
qtL1_4
##output messaging
if((TTH-qtTH)>0)
print("reject the null hypothesis for total hip")
if((TTH-qtTH)<=0)
print("you are not able to reject the null hypothesis for
total hip")
if((TL1_4-qtL1_4)>0)
print("reject the null hypothesis for lumbar spine")
if((TL1_4-qtL1_4)<=0)
print("you are not able to reject the null hypothesis for
lumbar spine")
##END: Unadjusted Analysis
##BEGIN Adjusted Analysis Using Multivariable Linear
Regression
##visualize distributions of participant demographic and
behavioral characteristics
##can also do str function for each predictor to examine
potential extreme values
##can also do stem and leaf plots
##can do scatterplots to evaluate need for transformations
##can also test for correlations using Pearsons/Spearmans
##can test linearity using Shapiro-Wilk's
##can evaluate leverage values
##can do QQ plots
##can do Jackknife Residuals
##can do Cook's Distance
##can evaluate collinearity with rcorr function
##can do Variance Inflation Factors (VIF>10 interrogation)
##can evaluate multicollinearity with Tolerance Values,
Eigenvalues, Condition Indices/Numbers
par(mfrow=c(3,2))
hist(data$age)
hist(data$risks)
hist(data$family)
hist(data$conditions)
hist(data$medications)
hist(data$diet)
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##negative change in L spine
fitnL1_4<-lm(data$bigndeltaL1_4~
(data$apheresis)+
(data$age)+
(as.factor(data$risks))+
(as.factor(data$family))+
(as.factor(data$conditions))+
(as.factor(data$medications))+
(as.factor(data$diet))+
(data$BMI)+
(data$pre_L1_4)+
(data$Na)+
(data$K)+
(data$Cl)+
(data$CO2)+
(data$anion)+
(data$urea)+
(data$creat)+
(data$gluc)+
(data$alkphos)+
(data$AST)+
(data$ALT)+
(data$Ca)+
(data$P)+
(data$prot)+
(data$alb)+
(data$bili)+
(data$test))
summary(fitnL1_4)
anova(fitnL1_4)
##stepwise backwards elimination for negative change in L
spine
stepnL1_4<-stepAIC(fitnL1_4,direction="backward")
stepnL1_4$anova
##positive change in L spine
fitpL1_4<-lm(data$bigpdeltaL1_4~
(data$apheresis)+
(data$age)+
(as.factor(data$risks))+
(as.factor(data$family))+
(as.factor(data$conditions))+
(as.factor(data$medications))+
(as.factor(data$diet))+
(data$BMI)+
(data$pre_L1_4)+
(data$Na)+
(data$K)+
(data$Cl)+
(data$CO2)+
(data$anion)+
(data$urea)+
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(data$creat)+
(data$gluc)+
(data$alkphos)+
(data$AST)+
(data$ALT)+
(data$Ca)+
(data$P)+
(data$prot)+
(data$alb)+
(data$bili)+
(data$test))
summary(fitpL1_4)
anova(fitpL1_4)
##stepwise backwards elimination for positive change in L
spine
steppL1_4<-stepAIC(fitpL1_4,direction="backward")
steppL1_4$anova
##negative change in total hip
fitnTH<-lm(data$bigndeltaTH~
(data$apheresis)+
(data$age)+
(as.factor(data$risks))+
(as.factor(data$family))+
(as.factor(data$conditions))+
(as.factor(data$medications))+
(as.factor(data$diet))+
(data$BMI)+
(data$pre_TH)+
(data$Na)+
(data$K)+
(data$Cl)+
(data$CO2)+
(data$anion)+
(data$urea)+
(data$creat)+
(data$gluc)+
(data$alkphos)+
(data$AST)+
(data$ALT)+
(data$Ca)+
(data$P)+
(data$prot)+
(data$alb)+
(data$bili)+
(data$test))
summary(fitnTH)
anova(fitnTH)
##stepwise backwards elimination for negative change in L
spine
stepnTH<-stepAIC(fitnTH,direction="backward")
stepnTH$anova
##positive change in TH
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fitpTH<-lm(data$bigpdeltaTH~
(data$apheresis)+
(data$age)+
(as.factor(data$risks))+
(as.factor(data$family))+
(as.factor(data$conditions))+
(as.factor(data$medications))+
(as.factor(data$diet))+
(data$BMI)+
(data$pre_TH)+
(data$Na)+
(data$K)+
(data$Cl)+
(data$CO2)+
(data$anion)+
(data$urea)+
(data$creat)+
(data$gluc)+
(data$alkphos)+
(data$AST)+
(data$ALT)+
(data$Ca)+
(data$P)+
(data$prot)+
(data$alb)+
(data$bili)+
(data$test))
summary(fitpTH)
anova(fitpTH)
##stepwise backwards elimination for positive change in L
spine
steppTH<-stepAIC(fitpTH,direction="backward")
steppTH$anova
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Appendix 12 – IBC Approval
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Appendix 13 – Radiation Safety Approval
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Appendix 14 – MCW IRB Approval
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Appendix 15 – DXA Quality Control Records
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